James Emmett Herndon II | Scholars@Duke

James Emmett Herndon II
Professor of Biostatistics and Bioinformatics

Current research interests have application to the design and analysis of cancer clinical trials. Specifically, interests include the use of time-dependent covariables within survival models, the design of phase II cancer clinical trials which minimize some of the logistical problems associated with their conduct, and the analysis of longitudinal studies with informative censoring (in particular, quality of life studies of patients with advanced cancer).

Current Appointments & Affiliations

Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics, Basic Science Departments 2015
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1988

Contact Information

2424 Erwin Road, 8020 Hock Plaza, Durham, NC 27705
Duke Box 2717, Durham, NC 27710
james.herndon@duke.edu (919) 668-8145

Background
Education, Training, & Certifications
- Ph.D., University of North Carolina - Chapel Hill 1988
Duke Appointment History
- Associate Professor of Biostatistics and Bionformatics, Biostatistics & Bioinformatics, Basic Science Departments 2000 - 2015
- Associate Professor in Community and Family Medicine, Family Medicine and Community Health, Clinical Science Departments 2000
- Assistant Research Professor in Community and Family Medicine, Family Medicine and Community Health, Clinical Science Departments 1998 - 1999
- Assistant Professor in Community and Family Medicine, Family Medicine and Community Health, Clinical Science Departments 1988 - 1998
Expertise
Subject Headings
Research
Selected Grants
- Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine Efficacy awarded by National Institutes of Health 2018 - 2023
- Innate Antiviral Signals for Cancer Immunotherapy awarded by National Institutes of Health 2018 - 2023
- A Novel Immune Modulating Antibody for the Treatment of Lung Cancer awarded by Department of Defense 2019 - 2022
- A Phase 1/2 Trial for Patients with Newly Diagnosed High Grade Glioma Treated with Concurrent Radiation Therapy, Temozolomide, and BMX-001 awarded by BioMimetix JV LLC 2020 - 2022
- Unraveling the Role of ABL 1 and 2 Drivers of Medulloblastoma Leptomeningeal Metastases awarded by National Institutes of Health 2020 - 2021
- CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy awarded by National Institutes of Health 2016 - 2021
- BATF3+ Dendritic Cells for the Treatment of Malignant Gliomas awarded by Department of Defense 2020 - 2021
- Improving CAR T cell immunotherapy for heterogeneous brain tumors awarded by University of Florida 2019 - 2021
- Is Low Tumor Mutational Burden Predictive of Response to Oncolytic Polio Virus Therapy in Recurrent Glioblastoma? awarded by National Institutes of Health 2019 - 2021
- The Role of CD155 in Leptomeningeal Dissemination and Oncolytic Virus Susceptibility in the Medulloblastoma Microenvironment awarded by Department of Defense 2018 - 2021
- Regional Oncolytic Poliovirus Immunotherapy for Breast Cancer awarded by Department of Defense 2016 - 2021
- Human EGFRvIII-specific BiTE for the treatment of Glioblastoma awarded by National Institutes of Health 2015 - 2021
- Poliovirus-Instigated APC Responses Against BRaf(V600E) for Pediatric Brain Tumor Immunotherapy awarded by V Foundation for Cancer Research 2018 - 2021
- BMX-001 as a therapeutic agent for treatment of multiple brain metastases awarded by BioMimetix JV LLC 2020
- Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma awarded by Annias Immunotherapeutics, Inc. 2015 - 2020
- Ph 1/2 Trial for Patients with Newly Diagnosed High Grade Glioma Treated with Concurrent Radiation Therapy, Temozolomide, and BMX-001 awarded by BioMimetix JV LLC 2015 - 2020
- Lost and Found: The Bone Marrow as Counterproductive Site of T cell Sequestration in GBM awarded by Sontag Foundation 2015 - 2019
- Randomized Trial of Optimal Type of Aerobic Training in Breast Cancer awarded by Memorial Sloan-Kettering Cancer Center 2015 - 2019
- EGFRvIII-targeted Bispecific T cell Engagers for brain tumors awarded by National Institutes of Health 2013 - 2019
- Development of a Therapeutic for Brain Tumor Immunotherapy awarded by National Institutes of Health 2018 - 2019
- Systemically administrered EGRFvIII-targeted bispecific antibody as an immunotherapeutic for glioblastoma. awarded by National Institutes of Health 2015 - 2019
- Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells awarded by National Institutes of Health 2013 - 2018
- Brain Tumor Targeting Using Tumor-Specific Neuroimmunology awarded by National Institutes of Health 2014 - 2018
- A clinically-relevant anti-CD27 agonist antibody as a vaccine adjuvant for brain tumor immunotherapy awarded by National Institutes of Health 2016 - 2017
- Improving Adherence to Recommended Surveillance in Breast Cancer Survivors awarded by National Institutes of Health 2010 - 2015
- Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide awarded by National Institutes of Health 2009 - 2014
- Targeting EGFRvIII in Brain Tumors with Bispecific Antibodies awarded by National Institutes of Health 2013 - 2014
- (PQA5) 'Dose and Mechanisms of Exercise in Breast Cancer Prevention' awarded by National Institutes of Health 2013 - 2014
- Aerobic Training During or After Adjuvant Therapy: A Randomized Trial awarded by National Institutes of Health 2012 - 2014
- Phase II Trial of Aerobic Training in Metastatic Breast Cancer awarded by National Institutes of Health 2010 - 2014
- Randomized Trial of Optimal Type of Aerobic Training in Breast Cancer awarded by National Institutes of Health 2010 - 2014
- Modulation of the blood-tumor barrier through targeted suppression of claudin 5 awarded by National Institutes of Health 2011 - 2013
- Reversal of CMV-specific immune deficits in patients with glioblastoma awarded by National Institutes of Health 2009 - 2013
- Brain Tumors - Immunological and Biological Studies awarded by National Institutes of Health 2001 - 2013
- Neuroimmunology of Vaccines in Adoptive T-cell Therapy for Brain Tumor awarded by National Institutes of Health 2010 - 2012
- Pre-clinical Translation of Regulatory T-cell Inhibition in Brain Tumors awarded by National Institutes of Health 2010 - 2012
- The Role of OTX2 in Molecular Pathogenesis of Medulloblastoma awarded by National Institutes of Health 2006 - 2012
- Gene Targeted Therapy of Brain Tumors awarded by National Institutes of Health 2009 - 2012
- Prospective Validation of Genomic Signatures of Chemosensitivity in NSCLC awarded by National Institutes of Health 2009 - 2010
- Discovery of Biomarkers for Lung Cancer Metastasis awarded by National Institutes of Health 2005 - 2010
- Effect on IL-2R Antibody on Regulatory T-cells in Patients with Malignant Gliomas awarded by National Institutes of Health 2008 - 2009
- Palliative Oxygen for the Relief of Breathlessness awarded by National Institutes of Health 2006 - 2009
- Serum Biomarkers for Early Diagnosis of NSCLC awarded by Johns Hopkins University 2007 - 2009
- Stem Cell-Like Glioma Cells in Angiogenesis awarded by National Institutes of Health 2008 - 2009
- DNA Methylation and GSTP1 Gene Regulation in Gliomas awarded by National Institutes of Health 2002 - 2008
- Phase I/II Trial of ZD1839 and Celecoxib in Ex-Smokers awarded by National Institutes of Health 2002 - 2007
- Measurement of Hypoxia in Non-Small Cell Lung Carcinoma awarded by National Institutes of Health 2002 - 2006
- ACOSOG-Statistics and Data Coordinating Center awarded by National Institutes of Health 2000 - 2005
- ZD1839 Therapy of Glioblastoma Multiforme awarded by National Institutes of Health 2001 - 2003
- Using Plasma TGFB1 Levels to Escalate Radiotherapy Doses awarded by National Institutes of Health 2000 - 2003
- Src On Primary And Matastatic Tumors Of The Cns awarded by National Institutes of Health 1994 - 1999
- Src On Primary And Metastatic Tumors Of The Cns awarded by National Institutes of Health 1997 - 1999
- Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
- Comprehensive Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
- Cancer And Leukemia Group B - Statistical Center awarded by National Institutes of Health 1994 - 1998
- Cancer And Leukemia Group B Statistical Center awarded by National Institutes of Health 1982 - 1998
- Src On Malignant Human Gliomas And Medulloblastomas awarded by National Institutes of Health 1992 - 1994
- Comprehensive Cancer Center Core Support Grant awarded by National Institutes of Health 1992 - 1993
- Cancer And Leukemia Group B Statistical Center awarded by National Institutes of Health 1992 - 1993
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Batich, Kristen A., Duane A. Mitchell, Patrick Healy, James E. Herndon, and John H. Sampson. “Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.” Clin Cancer Res 26, no. 20 (October 15, 2020): 5297–5303. https://doi.org/10.1158/1078-0432.CCR-20-1082.
    Full Text Link to Item
  - Affronti, Mary Lou, James E. Herndon, and Mallika P. Patel. “Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide".” Support Care Cancer, September 3, 2020. https://doi.org/10.1007/s00520-020-05726-0.
    Full Text Link to Item
  - Patel, Mallika P., Sarah Woodring, Dina M. Randazzo, Henry S. Friedman, Annick Desjardins, Patrick Healy, James E. Herndon, et al. “Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.” Support Care Cancer 28, no. 5 (May 2020): 2229–38. https://doi.org/10.1007/s00520-019-05039-x.
    Full Text Link to Item
  - Tsvankin, Vadim, Rintaro Hashizume, Hiroaki Katagi, James E. Herndon, Christopher Lascola, Talaignair N. Venkatraman, Daniel Picard, Brainard Burrus, Oren J. Becher, and Eric M. Thompson. “ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.” Neurosurgery 86, no. 5 (May 2020): 742–51. https://doi.org/10.1093/neuros/nyz212.
    Full Text
  - Patel, Mallika P., John P. Kirkpatrick, Margaret O. Johnson, Patrick Healy, James E. Herndon, Eric S. Lipp, Elizabeth S. Miller, et al. “Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.” J Neurooncol 147, no. 2 (April 2020): 477–83. https://doi.org/10.1007/s11060-020-03446-3.
    Full Text Link to Item
  - Scott, Jessica M., Samantha M. Thomas, Jeffrey M. Peppercorn, James E. Herndon, Pamela S. Douglas, Michel G. Khouri, Chau T. Dang, et al. “Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With Primary Breast Cancer: A Randomized Controlled Trial.” Circulation 141, no. 7 (February 18, 2020): 560–70. https://doi.org/10.1161/CIRCULATIONAHA.119.043483.
    Full Text Link to Item
  - Kim, Jung-Young, Jennifer G. Jackman, Sarah Woodring, Frances McSherry, James E. Herndon, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “Second primary cancers in long-term survivors of glioblastoma.” Neurooncol Pract 6, no. 5 (September 2019): 386–91. https://doi.org/10.1093/nop/npz001.
    Full Text Link to Item
  - Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary L. Affronti, Eric S. Lipp, Charlene Flahiff, Elizabeth Miller, et al. “Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.” Complement Ther Clin Pract 36 (August 2019): 43–48. https://doi.org/10.1016/j.ctcp.2019.05.002.
    Full Text Link to Item
  - Hansen, Landon J., Ran Sun, Rui Yang, Simranjit X. Singh, Lee H. Chen, Christopher J. Pirozzi, Casey J. Moure, et al. “MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.” Cancer Res 79, no. 13 (July 1, 2019): 3383–94. https://doi.org/10.1158/0008-5472.CAN-18-1010.
    Full Text Link to Item
  - Desjardins, Annick, James E. Herndon, Frances McSherry, Arliene Ravelo, Eric S. Lipp, Patrick Healy, Katherine B. Peters, et al. “Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.” Health Sci Rep 2, no. 4 (April 2019): e114. https://doi.org/10.1002/hsr2.114.
    Full Text Link to Item
  - Chongsathidkiet, Pakawat, Christina Jackson, Shohei Koyama, Franziska Loebel, Xiuyu Cui, S Harrison Farber, Karolina Woroniecka, et al. “Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.” Nat Med 25, no. 3 (March 2019): 529. https://doi.org/10.1038/s41591-019-0355-0.
    Full Text Link to Item
  - Lipp, Eric S., Patrick Healy, Alan Austin, Alysha Clark, Tara Dalton, Kathryn Perkinson, James E. Herndon, et al. “MGMT: Immunohistochemical Detection in High-Grade Astrocytomas.” J Neuropathol Exp Neurol 78, no. 1 (January 1, 2019): 57–64. https://doi.org/10.1093/jnen/nly110.
    Full Text Link to Item
  - Suryadevara, Carter M., Rupen Desai, S Harrison Farber, Bryan D. Choi, Adam M. Swartz, Steven H. Shen, Patrick C. Gedeon, et al. “Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.” Clin Cancer Res 25, no. 1 (January 1, 2019): 358–68. https://doi.org/10.1158/1078-0432.CCR-18-1211.
    Full Text Link to Item
  - Affronti, Mary Lou, Dina Randazzo, Eric S. Lipp, Katherine B. Peters, Susan C. Herndon, Sarah Woodring, Patrick Healy, Christina K. Cone, James E. Herndon, and Susan M. Schneider. “Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma.” Semin Oncol Nurs 34, no. 5 (December 2018): 472–85. https://doi.org/10.1016/j.soncn.2018.10.006.
    Full Text Link to Item
  - Atik, Ahmet F., Carter M. Suryadevara, Ryan M. Schweller, Jennifer L. West, Patrick Healy, James E. Herndon Ii, Kendra L. Congdon, et al. “Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells.” J Clin Neurosci 56 (October 2018): 163–68. https://doi.org/10.1016/j.jocn.2018.06.005.
    Full Text Link to Item
  - Chongsathidkiet, Pakawat, Christina Jackson, Shohei Koyama, Franziska Loebel, Xiuyu Cui, S Harrison Farber, Karolina Woroniecka, et al. “Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.” Nat Med 24, no. 9 (September 2018): 1459–68. https://doi.org/10.1038/s41591-018-0135-2.
    Full Text Link to Item
  - Thompson, Eric M., Alexa Bramall, James E. Herndon, Michael D. Taylor, and Vijay Ramaswamy. “The clinical importance of medulloblastoma extent of resection: a systematic review.” J Neurooncol 139, no. 3 (September 2018): 523–39. https://doi.org/10.1007/s11060-018-2906-5.
    Full Text Link to Item
  - Affronti, Mary Lou, Jennifer Gamboa Jackman, Frances McSherry, James E. Herndon, Elwood C. Massey, Eric Lipp, Annick Desjardins, et al. “Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.” The Oncologist 23, no. 8 (August 2018): 889-e98. https://doi.org/10.1634/theoncologist.2018-0149.
    Full Text
  - Gedeon, Patrick C., Teilo H. Schaller, Satish K. Chitneni, Bryan D. Choi, Chien-Tsun Kuan, Carter M. Suryadevara, David J. Snyder, et al. “A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 24, no. 15 (August 2018): 3611–31. https://doi.org/10.1158/1078-0432.ccr-17-0126.
    Full Text
  - Desjardins, Annick, Matthias Gromeier, James E. Herndon, Nike Beaubier, Dani P. Bolognesi, Allan H. Friedman, Henry S. Friedman, et al. “Recurrent Glioblastoma Treated with Recombinant Poliovirus.” N Engl J Med 379, no. 2 (July 12, 2018): 150–61. https://doi.org/10.1056/NEJMoa1716435.
    Full Text Link to Item
  - Scott, Jessica M., Neil M. Iyengar, Tormod S. Nilsen, Meghan Michalski, Samantha M. Thomas, James Herndon, John Sasso, et al. “Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial.” Cancer 124, no. 12 (June 15, 2018): 2552–60. https://doi.org/10.1002/cncr.31368.
    Full Text Link to Item
  - Nilsen, Tormod S., Jessica M. Scott, Meghan Michalski, Catherine Capaci, Samantha Thomas, James E. Herndon, John Sasso, Neil D. Eves, and Lee W. Jones. “Novel Methods for Reporting of Exercise Dose and Adherence: An Exploratory Analysis.” Med Sci Sports Exerc 50, no. 6 (June 2018): 1134–41. https://doi.org/10.1249/MSS.0000000000001545.
    Full Text Link to Item
  - Peters, Katherine B., Eric S. Lipp, Elizabeth Miller, James E. Herndon, Frances McSherry, Annick Desjardins, David A. Reardon, and Henry S. Friedman. “Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.” Journal of Neuro Oncology 137, no. 2 (April 2018): 349–56. https://doi.org/10.1007/s11060-017-2724-1.
    Full Text
  - Dunn-Pirio, Anastasie M., Sarah Woodring, Eric Lipp, James E. Herndon, Patrick Healy, Mallika Weant, Dina Randazzo, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “Adjunctive perampanel for glioma-associated epilepsy.” Epilepsy Behav Case Rep 10 (2018): 114–17. https://doi.org/10.1016/j.ebcr.2018.09.003.
    Full Text Link to Item
  - Reap, Elizabeth A., Carter M. Suryadevara, Kristen A. Batich, Luis Sanchez-Perez, Gary E. Archer, Robert J. Schmittling, Pamela K. Norberg, et al. “Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.” Cancer Research 78, no. 1 (January 2018): 256–64. https://doi.org/10.1158/0008-5472.can-17-0469.
    Full Text
  - Suryadevara, Carter M., Rupen Desai, Melissa L. Abel, Katherine A. Riccione, Kristen A. Batich, Steven H. Shen, Pakawat Chongsathidkiet, et al. “Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.” Oncoimmunology 7, no. 6 (January 2018): e1434464. https://doi.org/10.1080/2162402x.2018.1434464.
    Full Text
  - Aliabadi, H., A. M. Nikpour, D. S. Yoo, J. E. Herndon, J. H. Sampson, and J. P. Kirkpatrick. “Pre-operative stereotactic radiosurgery treatment is preferred to post-operative treatment for smaller solitary brain metastases.” Chinese Neurosurgical Journal 3, no. 1 (October 3, 2017). https://doi.org/10.1186/s41016-017-0092-5.
    Full Text
  - Limon, Dror, Frances McSherry, James Herndon, John Sampson, Peter Fecci, Justus Adamson, Zhiheng Wang, et al. “Single fraction stereotactic radiosurgery for multiple brain metastases.” Advances in Radiation Oncology 2, no. 4 (October 2017): 555–63. https://doi.org/10.1016/j.adro.2017.09.002.
    Full Text Open Access Copy
  - Narloch, Jessica L., S Harrison Farber, Sarah Sammons, Frances McSherry, James E. Herndon, Jenny K. Hoang, Fang-Fang Yin, et al. “Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.” Neuro Oncol 19, no. 10 (October 1, 2017): 1391–97. https://doi.org/10.1093/neuonc/nox090.
    Full Text Link to Item
  - Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary Lou Affronti, Eric S. Lipp, Charlene Flahiff, Elizabeth Miller, et al. “A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.” J Neurooncol 134, no. 2 (September 2017): 363–69. https://doi.org/10.1007/s11060-017-2535-4.
    Full Text Link to Item
  - Campa, Michael J., Elizabeth B. Gottlin, James E. Herndon, and Edward F. Patz. “Rethinking Autoantibody Signature Panels for Cancer Diagnosis.” J Thorac Oncol 12, no. 6 (June 2017): 1011–14. https://doi.org/10.1016/j.jtho.2017.01.017.
    Full Text Link to Item
  - Batich, Kristen A., Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Smita K. Nair, Robert J. Schmittling, Pam Norberg, et al. “Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 23, no. 8 (April 2017): 1898–1909. https://doi.org/10.1158/1078-0432.ccr-16-2057.
    Full Text
  - Kelley, Michael J., Gautam Jha, Debra Shoemaker, James E. Herndon, Lin Gu, William T. Barry, Jeffrey Crawford, and Neal Ready. “Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.” Cancer Invest 35, no. 1 (January 2, 2017): 32–35. https://doi.org/10.1080/07357907.2016.1253710.
    Full Text Link to Item
  - Affronti, Mary Lou, Sarah Woodring, Katherine B. Peters, James E. Herndon, Frances McSherry, Patrick N. Healy, Annick Desjardins, James J. Vredenburgh, and Henry S. Friedman. “A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.” Ther Clin Risk Manag 13 (2017): 33–40. https://doi.org/10.2147/TCRM.S122480.
    Full Text Link to Item
  - Randazzo, Dina, and Katherine B. Peters. “Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.” Cns Oncol 5, no. 4 (October 2016): 241–49. https://doi.org/10.2217/cns-2016-0010.
    Full Text Link to Item
  - Weitzel, Douglas H., Artak Tovmasyan, Kathleen A. Ashcraft, Alina Boico, Samuel R. Birer, Kingshuk Roy Choudhury, James Herndon, et al. “Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier.” Environ Mol Mutagen 57, no. 5 (June 2016): 372–81. https://doi.org/10.1002/em.22021.
    Full Text Link to Item
  - Saraswathula, Anirudh, Elizabeth A. Reap, Bryan D. Choi, Robert J. Schmittling, Pamela K. Norberg, Elias J. Sayour, James E. Herndon, et al. “Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.” Cancer Immunology, Immunotherapy : Cii 65, no. 2 (February 2016): 205–11. https://doi.org/10.1007/s00262-015-1784-3.
    Full Text
  - Oldham, Mark, Paul Yoon, Zak Fathi, Wayne F. Beyer, Justus Adamson, Leihua Liu, David Alcorta, et al. “X-Ray Psoralen Activated Cancer Therapy (X-PACT).” Plos One 11, no. 9 (2016): e0162078. https://doi.org/10.1371/journal.pone.0162078.
    Full Text Open Access Copy Link to Item
  - Robertson, Matthew E., Frances McSherry, James E. Herndon, and Katherine B. Peters. “Insomnia and its associations in patients with recurrent glial neoplasms.” Springerplus 5, no. 1 (2016): 823. https://doi.org/10.1186/s40064-016-2578-6.
    Full Text Open Access Copy Link to Item
  - Kwon, Woocheol, Brandon A. Howard, James E. Herndon, and Edward F. Patz. “Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography".” J Thorac Oncol 10, no. 10 (October 2015): e102. https://doi.org/10.1097/JTO.0000000000000637.
    Full Text Open Access Copy Link to Item
  - Wysham, Nicholas G., Benjamin J. Miriovsky, David C. Currow, James E. Herndon, Gregory P. Samsa, Andrew Wilcock, and Amy P. Abernethy. “Practical Dyspnea Assessment: Relationship Between the 0-10 Numerical Rating Scale and the Four-Level Categorical Verbal Descriptor Scale of Dyspnea Intensity.” Journal of Pain and Symptom Management 50, no. 4 (October 2015): 480–87. https://doi.org/10.1016/j.jpainsymman.2015.04.015.
    Full Text
  - Peters, Katherine B., Emil Lou, Annick Desjardins, David A. Reardon, Eric S. Lipp, Elizabeth Miller, James E. Herndon, Frances McSherry, Henry S. Friedman, and James J. Vredenburgh. “Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.” Oncologist 20, no. 7 (July 2015): 727–28. https://doi.org/10.1634/theoncologist.2015-0135.
    Full Text Link to Item
  - Kwon, Woocheol, Brandon A. Howard, James E. Herndon, and Edward F. Patz. “FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.” J Thorac Oncol 10, no. 6 (June 2015): 897–902. https://doi.org/10.1097/JTO.0000000000000534.
    Full Text Link to Item
  - McLendon, Roger E., Eric Lipp, Diane Satterfield, Melissa Ehinger, Alan Austin, Debra Fleming, Kathryn Perkinson, et al. “Prognostic marker analysis in pediatric intracranial ependymomas.” J Neurooncol 122, no. 2 (April 2015): 255–61. https://doi.org/10.1007/s11060-014-1711-z.
    Full Text Link to Item
  - Mitchell, Duane A., Kristen A. Batich, Michael D. Gunn, Min-Nung Huang, Luis Sanchez-Perez, Smita K. Nair, Kendra L. Congdon, et al. “Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.” Nature 519, no. 7543 (March 19, 2015): 366–69. https://doi.org/10.1038/nature14320.
    Full Text Open Access Copy Link to Item
  - Tuchman, Sascha A., Amy Lane, Whitney E. Hornsby, Caroline Bishop, Samantha Thomas, James E. Herndon, Gwynn Long, Cristina Gasparetto, and Lee W. Jones. “Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study.” Clin Lymphoma Myeloma Leuk 15, no. 2 (February 2015): 103–9. https://doi.org/10.1016/j.clml.2014.09.002.
    Full Text Link to Item
  - Kirkpatrick, John P., Zhiheng Wang, John H. Sampson, Frances McSherry, James E. Herndon, Karen J. Allen, Eileen Duffy, et al. “Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial.” Int J Radiat Oncol Biol Phys 91, no. 1 (January 1, 2015): 100–108. https://doi.org/10.1016/j.ijrobp.2014.09.004.
    Full Text Link to Item
  - Weitzel, Douglas H., Artak Tovmasyan, Kathleen A. Ashcraft, Zrinka Rajic, Tin Weitner, Chunlei Liu, Wei Li, et al. “Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+.” Mol Cancer Ther 14, no. 1 (January 2015): 70–79. https://doi.org/10.1158/1535-7163.MCT-14-0343.
    Full Text Link to Item
  - Peters, Katherine B., Miranda J. West, Whitney E. Hornsby, Emily Waner, April D. Coan, Frances McSherry, James E. Herndon, Henry S. Friedman, Annick Desjardins, and Lee W. Jones. “Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.” J Neurooncol 120, no. 3 (December 2014): 499–506. https://doi.org/10.1007/s11060-014-1574-3.
    Full Text Link to Item
  - Kelsey, C. R., J. M. Scott, A. Lane, E. Schwitzer, M. J. West, S. Thomas, J. E. Herndon, et al. “Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study.” Bone Marrow Transplant 49, no. 10 (October 2014): 1330–36. https://doi.org/10.1038/bmt.2014.159.
    Full Text Link to Item
  - Kanaly, Charles W., Ankit I. Mehta, Dale Ding, Jenny K. Hoang, Peter G. Kranz, James E. Herndon, April Coan, et al. “A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma.” J Neurosurg 121, no. 3 (September 2014): 536–42. https://doi.org/10.3171/2014.4.JNS121952.
    Full Text Link to Item
  - Kenjale, Aarti A., Whitney E. Hornsby, Theresa Crowgey, Samantha Thomas, James E. Herndon, Michel G. Khouri, Amy R. Lane, et al. “Pre-exercise participation cardiovascular screening in a heterogeneous cohort of adult cancer patients.” Oncologist 19, no. 9 (September 2014): 999–1005. https://doi.org/10.1634/theoncologist.2014-0078.
    Full Text Link to Item
  - Affronti, Mary Lou, Susan M. Schneider, James E. Herndon, Susan Schlundt, and Henry S. Friedman. “Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.” Support Care Cancer 22, no. 7 (July 2014): 1897–1905. https://doi.org/10.1007/s00520-014-2136-0.
    Full Text Link to Item
  - Desjardins, A., J. H. Sampson, K. B. Peters, T. Ranjan, G. Vlahovic, S. Threatt, J. E. Herndon, et al. “Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.” Neuro Oncol 16 Suppl 3 (July 2014): iii43. https://doi.org/10.1093/neuonc/nou209.5.
    Full Text Link to Item
  - Yan, H., P. J. Killela, Z. J. Reitman, Y. Jiao, C. Bettegowda, N. Agrawal, L. A. Diaz, et al. “Tert promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.” Neuro Oncol 16 Suppl 3 (July 2014): iii5–6. https://doi.org/10.1093/neuonc/nou206.18.
    Full Text Link to Item
  - Crowgey, Theresa, Katherine B. Peters, Whitney E. Hornsby, Amy Lane, Frances McSherry, James E. Herndon, Miranda J. West, Christina L. Williams, and Lee W. Jones. “Relationship between exercise behavior, cardiorespiratory fitness, and cognitive function in early breast cancer patients treated with doxorubicin-containing chemotherapy: a pilot study.” Appl Physiol Nutr Metab 39, no. 6 (June 2014): 724–29. https://doi.org/10.1139/apnm-2013-0380.
    Full Text Link to Item
  - Jones, Lee W., Whitney E. Hornsby, Stephen J. Freedland, Amy Lane, Miranda J. West, Judd W. Moul, Michael N. Ferrandino, et al. “Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer.” Eur Urol 65, no. 5 (May 2014): 852–55. https://doi.org/10.1016/j.eururo.2013.11.009.
    Full Text Link to Item
  - Killela, Patrick J., Christopher J. Pirozzi, Patrick Healy, Zachary J. Reitman, Eric Lipp, B Ahmed Rasheed, Rui Yang, et al. “Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.” Oncotarget 5, no. 6 (March 30, 2014): 1515–25. https://doi.org/10.18632/oncotarget.1765.
    Full Text Open Access Copy Link to Item
  - Sampson, John H., Bryan D. Choi, Luis Sanchez-Perez, Carter M. Suryadevara, David J. Snyder, Catherine T. Flores, Robert J. Schmittling, et al. “EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.” Clin Cancer Res 20, no. 4 (February 15, 2014): 972–84. https://doi.org/10.1158/1078-0432.CCR-13-0709.
    Full Text Link to Item
  - Khouri, Michel G., Whitney E. Hornsby, Niels Risum, Eric J. Velazquez, Samantha Thomas, Amy Lane, Jessica M. Scott, et al. “Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.” Breast Cancer Res Treat 143, no. 3 (February 2014): 531–39. https://doi.org/10.1007/s10549-013-2818-1.
    Full Text Link to Item
  - Sampson, John H., Shivanand P. Lad, James E. Herndon, Robert M. Starke, and Douglas Kondziolka. “SEER insights.” J Neurosurg 120, no. 2 (February 2014): 297–98. https://doi.org/10.3171/2013.6.JNS13993.
    Full Text Link to Item
  - Choi, Bryan D., Carter M. Suryadevara, Patrick C. Gedeon, James E. Herndon, Luis Sanchez-Perez, Darell D. Bigner, and John H. Sampson. “Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.” J Clin Neurosci 21, no. 1 (January 2014): 189–90. https://doi.org/10.1016/j.jocn.2013.03.012.
    Full Text Link to Item
  - Hornsby, Whitney E., Pamela S. Douglas, Miranda J. West, Aarti A. Kenjale, Amy R. Lane, Emily R. Schwitzer, Kaitlin A. Ray, et al. “Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial.” Acta Oncol 53, no. 1 (January 2014): 65–74. https://doi.org/10.3109/0284186X.2013.781673.
    Full Text Link to Item
  - Miao, Hongsheng, Bryan D. Choi, Carter M. Suryadevara, Luis Sanchez-Perez, Shicheng Yang, Gabriel De Leon, Elias J. Sayour, et al. “EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.” Plos One 9, no. 4 (2014): e94281. https://doi.org/10.1371/journal.pone.0094281.
    Full Text Open Access Copy Link to Item
  - Roman, Michael A., Graeme J. Koelwyn, Neil D. Eves, Whitney E. Hornsby, Dorothy Watson, James E. Herndon Ii, Leslie Kohman, Gregory Loewen, and Lee W. Jones. “Comparison of performance status with peak oxygen consumption in operable patients with non-small-cell lung cancer.” Respirology 19, no. 1 (January 2014): 105–8. https://doi.org/10.1111/resp.12162.
    Full Text Link to Item
  - Denehy, Linda, Whitney E. Hornsby, James E. Herndon, Samantha Thomas, Neal E. Ready, Catherine L. Granger, Lauren Valera, Aarti A. Kenjale, Neil D. Eves, and Lee W. Jones. “Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer.” J Thorac Oncol 8, no. 12 (December 2013): 1545–50. https://doi.org/10.1097/JTO.0000000000000032.
    Full Text Link to Item
  - Choi, Bryan D., Patrick C. Gedeon, James E. Herndon, Gary E. Archer, Elizabeth A. Reap, Luis Sanchez-Perez, Duane A. Mitchell, Darell D. Bigner, and John H. Sampson. “Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.” Cancer Immunol Res 1, no. 3 (September 2013): 163. https://doi.org/10.1158/2326-6066.CIR-13-0049.
    Full Text Link to Item
  - Gururangan, S., G. A. Grant, T. Driscoll, G. Archer, E. J. Sayour, J. E. Herndon, H. S. Friedman, et al. “ADOPTIVE LYMPHOCYTE THERAPY (ALT) PLUS DENDRITIC CELL VACCINATION (DCV) AFTER MYELOABLATIVE (MA) OR NON-MYELOABLATIVE (NMA) CONDITIONING IN PATIENTS WITH RECURRENT CENTRAL PNET (C-PNET).” Pediatric Blood & Cancer 60 (September 1, 2013): 13–13.
    Link to Item
  - Patz, Edward F., Michael J. Campa, Elizabeth B. Gottlin, Priscilla R. Trotter, James E. Herndon, Don Kafader, Russell P. Grant, and Marcia Eisenberg. “Biomarkers to help guide management of patients with pulmonary nodules.” Am J Respir Crit Care Med 188, no. 4 (August 15, 2013): 461–65. https://doi.org/10.1164/rccm.201210-1760OC.
    Full Text Open Access Copy Link to Item
  - Cabrera, Alvin R., Kyle C. Cuneo, Annick Desjardins, John H. Sampson, Frances McSherry, James E. Herndon, Katherine B. Peters, et al. “Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.” Int J Radiat Oncol Biol Phys 86, no. 5 (August 1, 2013): 873–79. https://doi.org/10.1016/j.ijrobp.2013.04.029.
    Full Text Link to Item
  - Jiang, Xiaoyin, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jennifer A. Quinn, Alan D. Austin, James E. Herndon, Roger E. McLendon, and Henry S. Friedman. “O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.” J Neurooncol 114, no. 1 (August 2013): 135–40. https://doi.org/10.1007/s11060-013-1162-y.
    Full Text Link to Item
  - Sanchez-Perez, Luis, Bryan D. Choi, Elizabeth A. Reap, Elias J. Sayour, Pamela Norberg, Robert J. Schmittling, Gerald E. Archer, et al. “BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.” Cancer Immunol Immunother 62, no. 6 (June 2013): 983–87. https://doi.org/10.1007/s00262-013-1405-y.
    Full Text Link to Item
  - Lakoski, Susan G., Carolyn E. Barlow, Graeme J. Koelwyn, Whitney E. Hornsby, Jesse Hernandez, Laura F. Defina, Nina B. Radford, et al. “The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study.” Breast Cancer Res Treat 138, no. 3 (April 2013): 909–16. https://doi.org/10.1007/s10549-013-2478-1.
    Full Text Link to Item
  - Lou, Emil, Katherine B. Peters, Ashley L. Sumrall, Annick Desjardins, David A. Reardon, Eric S. Lipp, James E. Herndon, et al. “Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.” Cancer Med 2, no. 2 (April 2013): 185–95. https://doi.org/10.1002/cam4.58.
    Full Text Open Access Copy Link to Item
  - Herndon, James E., Alice B. Kornblith, Jimmie C. Holland, and Electra D. Paskett. “Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials.” Psychooncology 22, no. 2 (February 2013): 315–23. https://doi.org/10.1002/pon.2094.
    Full Text Open Access Copy Link to Item
  - Salama, April K. S., Nicole de Rosa, Randall P. Scheri, Scott K. Pruitt, James E. Herndon, Jennifer Marcello, Douglas S. Tyler, and Amy P. Abernethy. “Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.” Plos One 8, no. 3 (2013): e57665. https://doi.org/10.1371/journal.pone.0057665.
    Full Text Open Access Copy Link to Item
  - Sanchez-Perez, Luis A., Bryan D. Choi, Gary E. Archer, Xiuyu Cui, Catherine Flores, Laura A. Johnson, Robert J. Schmittling, et al. “Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.” Plos One 8, no. 3 (2013): e59082. https://doi.org/10.1371/journal.pone.0059082.
    Full Text Open Access Copy Link to Item
  - Zomorodi, Ali, James E. Herndon, and John H. Sampson. “Subarachnoid hemorrhage trials.” J Neurosurg 118, no. 1 (January 2013): 1–2. https://doi.org/10.3171/2012.5.JNS12730.
    Full Text Link to Item
  - Salama, April K. S., Nicole de Rosa, Randall P. Scheri, James E. Herndon, Douglas S. Tyler, Jennifer Marcello, Scott K. Pruitt, and Amy P. Abernethy. “The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost.” Cancer Invest 30, no. 9 (November 2012): 637–41. https://doi.org/10.3109/07357907.2012.726387.
    Full Text Link to Item
  - Reardon, D. A., J. E. Herndon, K. B. Peters, A. Desjardins, A. Coan, E. Lou, A. L. Sumrall, et al. “Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.” Br J Cancer 107, no. 9 (October 23, 2012): 1481–87. https://doi.org/10.1038/bjc.2012.415.
    Full Text Open Access Copy Link to Item
  - Pearce, Michelle J., April D. Coan, James E. Herndon, Harold G. Koenig, and Amy P. Abernethy. “Unmet spiritual care needs impact emotional and spiritual well-being in advanced cancer patients.” Support Care Cancer 20, no. 10 (October 2012): 2269–76. https://doi.org/10.1007/s00520-011-1335-1.
    Full Text Link to Item
  - Reardon, David A., Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, Sridharan Gururangan, Katherine B. Peters, et al. “Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.” Cancer 118, no. 19 (October 1, 2012): 4759–67. https://doi.org/10.1002/cncr.26541.
    Full Text Link to Item
  - Tcheung, Win J., Maria A. Selim, James E. Herndon, Amy P. Abernethy, and Kelly C. Nelson. “Clinicopathologic study of 85 cases of melanoma of the female genitalia.” J Am Acad Dermatol 67, no. 4 (October 2012): 598–605. https://doi.org/10.1016/j.jaad.2011.11.921.
    Full Text Link to Item
  - Lou, Emil, Ashley L. Sumrall, Scott Turner, Katherine B. Peters, Annick Desjardins, James J. Vredenburgh, Roger E. McLendon, et al. “Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.” J Neurooncol 109, no. 1 (August 2012): 63–70. https://doi.org/10.1007/s11060-012-0861-0.
    Full Text Link to Item
  - Jones, Lee W., Kerry S. Courneya, John R. Mackey, Hyman B. Muss, Edith N. Pituskin, Jessica M. Scott, Whitney E. Hornsby, et al. “Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.” J Clin Oncol 30, no. 20 (July 10, 2012): 2530–37. https://doi.org/10.1200/JCO.2011.39.9014.
    Full Text Link to Item
  - Reardon, David A., James J. Vredenburgh, Annick Desjardins, Katherine B. Peters, Sith Sathornsumetee, Stevie Threatt, John H. Sampson, et al. “Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.” J Neurooncol 108, no. 3 (July 2012): 499–506. https://doi.org/10.1007/s11060-012-0848-x.
    Full Text Link to Item
  - Jones, Lee W., Whitney E. Hornsby, Amy Goetzinger, Lindsay M. Forbes, Emily L. Sherrard, Morten Quist, Amy T. Lane, et al. “Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer.” Lung Cancer 76, no. 2 (May 2012): 248–52. https://doi.org/10.1016/j.lungcan.2011.10.009.
    Full Text Link to Item
  - Desjardins, Annick, David A. Reardon, April Coan, Jennifer Marcello, James E. Herndon, Leighann Bailey, Katherine B. Peters, Henry S. Friedman, and James J. Vredenburgh. “Bevacizumab and daily temozolomide for recurrent glioblastoma.” Cancer 118, no. 5 (March 1, 2012): 1302–12. https://doi.org/10.1002/cncr.26381.
    Full Text Link to Item
  - Reardon, David A., Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, et al. “Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.” J Neurooncol 107, no. 1 (March 2012): 155–64. https://doi.org/10.1007/s11060-011-0722-2.
    Full Text Link to Item
  - Reardon, David A., James E. Herndon, Katherine Peters, Annick Desjardins, April Coan, Emil Lou, Ashley Sumrall, et al. “Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.” J Neurooncol 107, no. 1 (March 2012): 213–21. https://doi.org/10.1007/s11060-011-0740-0.
    Full Text Link to Item
  - Sampson, John H., James E. Herndon, Roger E. McLendon, Vic Hasselblad, Anthony L. Asher, Matthew J. McGirt, and Eric D. Peterson. “Clinical data simplified.” J Neurosurg 116, no. 2 (February 2012): 346–48. https://doi.org/10.3171/2011.5.JNS11279.
    Full Text Link to Item
  - Reardon, David A., Andrew D. Norden, Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, John H. Sampson, et al. “Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.” J Neurooncol 106, no. 2 (January 2012): 409–15. https://doi.org/10.1007/s11060-011-0687-1.
    Full Text Link to Item
  - Sampson, John H., Robert J. Schmittling, Gary E. Archer, Kendra L. Congdon, Smita K. Nair, Elizabeth A. Reap, Annick Desjardins, et al. “A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.” Plos One 7, no. 2 (2012): e31046. https://doi.org/10.1371/journal.pone.0031046.
    Full Text Open Access Copy Link to Item
  - Vredenburgh, James J., Annick Desjardins, John P. Kirkpatrick, David A. Reardon, Katherine B. Peters, James E. Herndon, Jennifer Marcello, et al. “Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.” Int J Radiat Oncol Biol Phys 82, no. 1 (January 1, 2012): 58–66. https://doi.org/10.1016/j.ijrobp.2010.08.058.
    Full Text Link to Item
  - Zalutsky, Michael R., Abraham Boskovitz, Chien-Tsun Kuan, Charles N. Pegram, Joanne Ayriss, Carol J. Wikstrand, Anne F. Buckley, et al. “Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.” Nucl Med Biol 39, no. 1 (January 2012): 23–34. https://doi.org/10.1016/j.nucmedbio.2011.06.005.
    Full Text Link to Item
  - Desjardins, Annick, David A. Reardon, Katherine B. Peters, Stevie Threatt, April D. Coan, James E. Herndon, Allan H. Friedman, Henry S. Friedman, and James J. Vredenburgh. “A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.” J Neurooncol 105, no. 3 (December 2011): 601–6. https://doi.org/10.1007/s11060-011-0627-0.
    Full Text Link to Item
  - Reardon, David A., Annick Desjardins, Katherine B. Peters, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, et al. “Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.” Cancer 117, no. 23 (December 1, 2011): 5351–58. https://doi.org/10.1002/cncr.26188.
    Full Text Link to Item
  - Reardon, David A., James J. Vredenburgh, April Coan, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, Sith Sathornsumetee, Jeremy N. Rich, James E. Herndon, and Henry S. Friedman. “Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.” J Neurooncol 105, no. 3 (December 2011): 621–27. https://doi.org/10.1007/s11060-011-0631-4.
    Full Text Link to Item
  - Desjardins, Annick, David A. Reardon, Katherine B. Peters, James E. Herndon, Sridharan Gururangan, Julie Norfleet, Henry S. Friedman, and James J. Vredenburgh. “PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS.” Neuro Oncology 13 (November 1, 2011): 90–90.
    Link to Item
  - Kwatra, Madan M., Tara M. Porter, Kristine E. Brown, James E. Herndon, and Darell D. Bigner. “TRUNCATED NEUROKININ 1 RECEPTOR: EXPRESSION IN PRIMARY GLIOBLASTOMAS AND RELATIONSHIP WITH PATIENT SURVIVAL.” Neuro Oncology 13 (November 1, 2011): 82–82.
    Link to Item
  - Mitchell, Duane A., Gary E. Archer, Henry S. Friedman, James E. Herndon, Darell D. Bigner, and John H. Sampson. “DENDRITIC CELL VACCINES TARGETING CYTOMEGALOVIRUS IN GLIOBLASTOMA.” Neuro Oncology 13 (November 1, 2011): 39–39.
    Link to Item
  - Vredenburgh, James J., Annick Desjardins, David A. Reardon, Katherine B. Peters, John P. Kirkpatrick, James E. Herndon, April D. Coan, et al. “THE ADDITION OF BEVACIZUMAB TO TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME.” Neuro Oncology 13 (November 1, 2011): 89–90.
    Link to Item
  - Gottlin, Elizabeth B., Rex C. Bentley, Michael J. Campa, David S. Pisetsky, James E. Herndon, and Edward F. Patz. “The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.” J Thorac Oncol 6, no. 10 (October 2011): 1687–90. https://doi.org/10.1097/JTO.0b013e3182217bec.
    Full Text Link to Item
  - Mitchell, Duane A., Xiuyu Cui, Robert J. Schmittling, Luis Sanchez-Perez, David J. Snyder, Kendra L. Congdon, Gary E. Archer, et al. “Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.” Blood 118, no. 11 (September 15, 2011): 3003–12. https://doi.org/10.1182/blood-2011-02-334565.
    Full Text Link to Item
  - Mehta, A. I., O. Persson, J. E. Herndon, G. E. Archer, R. McLendon, A. B. Heimberger, D. A. Mitchell, D. D. Bigner, and J. H. Sampson. “Reply to M.S. Lesniak.” Journal of Clinical Oncology 29, no. 22 (August 1, 2011): 3105–6. https://doi.org/10.1200/JCO.2011.35.0256.
    Full Text
  - Sampson, John H., James E. Herndon, Allan H. Friedman, and Amy P. Abernethy. “Epidemiology.” J Neurosurg 115, no. 2 (August 2011): 256–57. https://doi.org/10.3171/2011.1.JNS102066.
    Full Text Link to Item
  - Ruden, Emily, David A. Reardon, April D. Coan, James E. Herndon, Whitney E. Hornsby, Miranda West, Diane R. Fels, et al. “Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.” J Clin Oncol 29, no. 21 (July 20, 2011): 2918–23. https://doi.org/10.1200/JCO.2011.34.9852.
    Full Text Link to Item
  - Kuan, Chien-Tsun, Kenji Wakiya, Stephen T. Keir, Jianjun Li, James E. Herndon, Ira Pastan, and Darell D. Bigner. “Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.” Int J Cancer 129, no. 1 (July 1, 2011): 111–21. https://doi.org/10.1002/ijc.25645.
    Full Text Link to Item
  - Vredenburgh, James J., Annick Desjardins, David A. Reardon, Katherine B. Peters, James E. Herndon, Jennifer Marcello, John P. Kirkpatrick, et al. “The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.” Clin Cancer Res 17, no. 12 (June 15, 2011): 4119–24. https://doi.org/10.1158/1078-0432.CCR-11-0120.
    Full Text Link to Item
  - Heimberger, A. B., D. D. Bigner, J. E. Herndon, and J. H. Sampson. “Reply to M.C. Chamberlain.” Journal of Clinical Oncology 29, no. 17 (June 10, 2011). https://doi.org/10.1200/JCO.2010.34.1453.
    Full Text
  - Reardon, David A., Annick Desjardins, Katherine Peters, Sridharan Gururangan, John Sampson, Jeremy N. Rich, Roger McLendon, et al. “Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.” J Neurooncol 103, no. 2 (June 2011): 371–79. https://doi.org/10.1007/s11060-010-0403-6.
    Full Text Link to Item
  - Cuneo, K. C., A. R. Cabrera, J. H. Sampson, K. J. Allen, J. J. Vredenburgh, K. Peters, Z. Chang, et al. “Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma.” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 2082–2082. https://doi.org/10.1200/jco.2011.29.15_suppl.2082.
    Full Text
  - Cuneo, K. C., A. R. Cabrera, J. H. Sampson, K. J. Allen, J. J. Vredenburgh, K. Peters, Z. Chang, et al. “Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 2082.
    Link to Item
  - Desjardins, A., D. A. Reardon, J. J. Vredenburgh, K. Peters, M. Trikha, J. James, M. Gardner, A. Brickhouse, J. E. Herndon, and H. S. Friedman. “A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED).” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 2070–2070. https://doi.org/10.1200/jco.2011.29.15_suppl.2070.
    Full Text
  - Desjardins, A., D. A. Reardon, J. J. Vredenburgh, K. Peters, M. Trikha, J. James, M. Gardner, A. Brickhouse, J. E. Herndon, and H. S. Friedman. “A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED).” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 2070.
    Link to Item
  - Lou, E., D. A. Reardon, K. Peters, A. Desjardins, J. E. Herndon, A. D. Coan, S. G. Turner, et al. “Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 2055–2055. https://doi.org/10.1200/jco.2011.29.15_suppl.2055.
    Full Text
  - Lou, E., D. A. Reardon, K. Peters, A. Desjardins, J. E. Herndon, A. D. Coan, S. G. Turner, et al. “Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 2055.
    Link to Item
  - Reardon, D. A., J. J. Vredenburgh, A. Desjardins, K. Peters, A. D. Coan, J. E. Herndon, and H. S. Friedman. “Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials.” Journal of Clinical Oncology 29, no. 15 (May 20, 2011).
    Link to Item
  - Reardon, D. A., J. J. Vredenburgh, A. Desjardins, K. Peters, A. D. Coan, J. E. Herndon, and H. S. Friedman. “Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 2030.
    Link to Item
  - Sampson, John H., and James E. Herndon. “Resection of vestibular schwannomas.” J Neurosurg 114, no. 5 (May 2011): 1216–17. https://doi.org/10.3171/2010.8.JNS10765.
    Full Text Link to Item
  - Smith, Sophia K., James E. Herndon, H Kim Lyerly, April Coan, Jane L. Wheeler, Tina Staley, and Amy P. Abernethy. “Correlates of quality of life-related outcomes in breast cancer patients participating in the Pathfinders pilot study.” Psychooncology 20, no. 5 (May 2011): 559–64. https://doi.org/10.1002/pon.1770.
    Full Text Link to Item
  - Reardon, David A., Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, et al. “A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.” J Natl Compr Canc Netw 9, no. 4 (April 2011): 414–27. https://doi.org/10.6004/jnccn.2011.0038.
    Full Text Link to Item
  - Sampson, John H., Kenneth D. Aldape, Gary E. Archer, April Coan, Annick Desjardins, Allan H. Friedman, Henry S. Friedman, et al. “Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.” Neuro Oncol 13, no. 3 (March 2011): 324–33. https://doi.org/10.1093/neuonc/noq157.
    Full Text Link to Item
  - Reardon, David A., James J. Vredenburgh, Annick Desjardins, Katherine Peters, Sridharan Gururangan, John H. Sampson, Jennifer Marcello, et al. “Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.” J Neurooncol 101, no. 1 (January 2011): 57–66. https://doi.org/10.1007/s11060-010-0217-6.
    Full Text Link to Item
  - Sathornsumetee, Sith, Annick Desjardins, James J. Vredenburgh, Roger E. McLendon, Jennifer Marcello, James E. Herndon, Alyssa Mathe, et al. “Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.” Neuro Oncol 12, no. 12 (December 2010): 1300–1310. https://doi.org/10.1093/neuonc/noq099.
    Full Text Link to Item
  - Sampson, John H., Amy B. Heimberger, Gary E. Archer, Kenneth D. Aldape, Allan H. Friedman, Henry S. Friedman, Mark R. Gilbert, et al. “Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.” J Clin Oncol 28, no. 31 (November 1, 2010): 4722–29. https://doi.org/10.1200/JCO.2010.28.6963.
    Full Text Link to Item
  - Jones, Lee W., Dorothy Watson, James E. Herndon, Neil D. Eves, Benjamin E. Haithcock, Gregory Loewen, and Leslie Kohman. “Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer.” Cancer 116, no. 20 (October 15, 2010): 4825–32. https://doi.org/10.1002/cncr.25396.
    Full Text Link to Item
  - Jones, Lee W., Pamela S. Douglas, Neil D. Eves, P Kelly Marcom, William E. Kraus, James E. Herndon, Brant A. Inman, Jason D. Allen, and Jeffrey Peppercorn. “Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer.” Bmc Cancer 10 (October 6, 2010): 531. https://doi.org/10.1186/1471-2407-10-531.
    Full Text Open Access Copy Link to Item
  - Abernethy, Amy P., Syed Yousuf Zafar, Hope Uronis, Jane L. Wheeler, April Coan, Krista Rowe, Rebecca A. Shelby, Robin Fowler, and James E. Herndon. “Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients.” J Pain Symptom Manage 40, no. 4 (October 2010): 545–58. https://doi.org/10.1016/j.jpainsymman.2010.01.017.
    Full Text Link to Item
  - Ding, Dale, Charles W. Kanaly, Thomas J. Cummings, James E. Herndon, Raghu Raghavan, and John H. Sampson. “Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321.” Neurol Res 32, no. 8 (October 2010): 810–15. https://doi.org/10.1179/174367509X12581069052090.
    Full Text Link to Item
  - Abernethy, Amy P., Christine F. McDonald, Peter A. Frith, Katherine Clark, James E. Herndon, Jennifer Marcello, Iven H. Young, et al. “Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial.” Lancet 376, no. 9743 (September 4, 2010): 784–93. https://doi.org/10.1016/S0140-6736(10)61115-4.
    Full Text Link to Item
  - Kuan, Chien-Tsun, Kenji Wakiya, James E. Herndon, Eric S. Lipp, Charles N. Pegram, Gregory J. Riggins, Ahmed Rasheed, et al. “MRP3: a molecular target for human glioblastoma multiforme immunotherapy.” Bmc Cancer 10 (September 1, 2010): 468. https://doi.org/10.1186/1471-2407-10-468.
    Full Text Open Access Copy Link to Item
  - Sampson, John H., Gary Archer, Christoph Pedain, Eva Wembacher-Schröder, Manfred Westphal, Sandeep Kunwar, Michael A. Vogelbaum, et al. “Poor drug distribution as a possible explanation for the results of the PRECISE trial.” J Neurosurg 113, no. 2 (August 2010): 301–9. https://doi.org/10.3171/2009.11.JNS091052.
    Full Text Link to Item
  - Abernethy, Amy P., James E. Herndon, April Coan, Tina Staley, Jane L. Wheeler, Krista Rowe, Sophia K. Smith, H. Shaw, and H Kim Lyerly. “Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients.” Support Care Cancer 18, no. 7 (July 2010): 893–98. https://doi.org/10.1007/s00520-010-0823-z.
    Full Text Link to Item
  - Friedman, Daphne R., April D. Coan, Sophia K. Smith, James E. Herndon, and Amy P. Abernethy. “Informational needs assessment of non-Hodgkin lymphoma survivors and their physicians.” Am J Hematol 85, no. 7 (July 2010): 528–32. https://doi.org/10.1002/ajh.21725.
    Full Text Link to Item
  - Brickhouse, A., J. J. Vredenburgh, S. Gururangan, D. A. Reardon, A. Desjardins, K. Peters, J. E. Herndon, J. Norfleet, J. Marcello, and H. S. Friedman. “Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG).” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2038–2038. https://doi.org/10.1200/jco.2010.28.15_suppl.2038.
    Full Text
  - Desjardins, A., J. J. Vredenburgh, D. A. Reardon, J. E. Herndon, J. Marcello, K. Peters, S. Gururangan, S. Sathornsumetee, J. N. Rich, and H. S. Friedman. “Long-term survival from the initial trial of bevacizumab and irinotecan.” Journal of Clinical Oncology 28, no. 15 (May 20, 2010).
    Link to Item
  - Gururangan, S., J. J. Vredenburgh, A. Desjardins, K. Peters, J. E. Herndon, R. E. McLendon, D. Janney, H. S. Friedman, and D. A. Reardon. “CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2089–2089. https://doi.org/10.1200/jco.2010.28.15_suppl.2089.
    Full Text
  - Kirkpatrick, J., J. J. Vredenburgh, D. A. Reardon, A. Desjardins, K. Peters, S. Gururangan, J. E. Herndon, J. Marcello, S. Woodring, and H. S. Friedman. “Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2073–2073. https://doi.org/10.1200/jco.2010.28.15_suppl.2073.
    Full Text
  - Sathornsumetee, S., A. Desjardins, J. J. Vredenburgh, R. E. McLendon, J. Marcello, J. E. Herndon, J. Norfleet, S. Gururangan, H. S. Friedman, and D. A. Reardon. “Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2055–2055. https://doi.org/10.1200/jco.2010.28.15_suppl.2055.
    Full Text
  - Vredenburgh, J. J., A. Desjardins, D. A. Reardon, K. Peters, J. Kirkpatrick, J. E. Herndon, J. Marcello, L. Bailey, S. Threatt, and H. S. Friedman. “Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM).” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2023–2023. https://doi.org/10.1200/jco.2010.28.15_suppl.2023.
    Full Text
  - Ding, D., C. W. Kanaly, D. D. Bigner, T. J. Cummings, J. E. Herndon, I. Pastan, R. Raghavan, and J. H. Sampson. “Erratum: Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1 (Journal of Neuro-Oncology DOI 10.1007/s11060-009-0046-7).” Journal of Neuro Oncology 98, no. 1 (May 1, 2010): 9. https://doi.org/10.1007/s11060-010-0183-z.
    Full Text
  - Ding, Dale, Charles W. Kanaly, Darrell D. Bigner, Thomas J. Cummings, James E. Herndon, Ira Pastan, Raghu Raghavan, and John H. Sampson. “Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.” J Neurooncol 98, no. 1 (May 2010): 1–7. https://doi.org/10.1007/s11060-009-0046-7.
    Full Text Link to Item
  - Jones, L. W., B. L. Viglianti, J. A. Tashjian, S. M. Kothadia, S. T. Keir, S. J. Freedland, M. Q. Potter, et al. “Erratum: Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer (Journal of Applied Physiology (2010) 108: (343-348) DOI: 10.1152/japplphysiol.00424.2009).” Journal of Applied Physiology 108, no. 4 (April 1, 2010): 1021. https://doi.org/10.1152/japplphysiol.zdg-9024-corr.2010.
    Full Text
  - Jones, Lee W., Benjamin L. Viglianti, Jessica A. Tashjian, Sejal M. Kothadia, Stephen T. Keir, Stephen J. Freedland, Michael Q. Potter, et al. “Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer.” J Appl Physiol (1985) 108, no. 2 (February 2010): 343–48. https://doi.org/10.1152/japplphysiol.00424.2009.
    Full Text Link to Item
  - Reardon, David A., Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, James E. Herndon, Jennifer Marcello, et al. “Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.” J Neurooncol 96, no. 2 (January 2010): 219–30. https://doi.org/10.1007/s11060-009-9950-0.
    Full Text Link to Item
  - Zafar, S Yousuf, Jennifer E. Marcello, Jane L. Wheeler, Krista L. Rowe, Michael A. Morse, James E. Herndon, and Amy P. Abernethy. “Treatment-related toxicity and supportive care in metastatic colorectal cancer.” J Support Oncol 8, no. 1 (January 2010): 15–20.
    Link to Item
  - Reardon, D. A., A. Desjardins, J. J. Vredenburgh, S. Gururangan, J. H. Sampson, S. Sathornsumetee, R. E. McLendon, et al. “Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.” Br J Cancer 101, no. 12 (December 15, 2009): 1986–94. https://doi.org/10.1038/sj.bjc.6605412.
    Full Text Open Access Copy Link to Item
  - Grunberg, S. M., J. Weeks, W. F. Magnan, J. Herndon, M. L. Naughton, K. L. Blackwell, M. E. Wood, et al. “Determination of utility scores for control of chemotherapy-induced nausea or vomiting - CALGB 309801.” Journal of Supportive Oncology 7, no. 5 (December 1, 2009).
  - Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Allan H. Friedman, John H. Sampson, Roger E. McLendon, James E. Herndon, and Henry S. Friedman. “Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.” J Neurooncol 95, no. 3 (December 2009): 393–400. https://doi.org/10.1007/s11060-009-9937-x.
    Full Text Link to Item
  - Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, et al. “Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.” Neuro Oncol 11, no. 5 (October 2009): 556–61. https://doi.org/10.1215/15228517-2009-007.
    Full Text Link to Item
  - Sampson, John H., Gary E. Archer, Duane A. Mitchell, Amy B. Heimberger, James E. Herndon, Denise Lally-Goss, Sharon McGehee-Norman, et al. “An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.” Mol Cancer Ther 8, no. 10 (October 2009): 2773–79. https://doi.org/10.1158/1535-7163.MCT-09-0124.
    Full Text Link to Item
  - Stinchcombe, Thomas E., Lydia Hodgson, II James E. Herndon, Michael Kelley, M Giulia Cicchetti, Nithya Ramnath, Harvey Niell, et al. “Identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801.” Journal of Thoracic Oncology 4, no. 9 (September 1, 2009): S522–23.
    Link to Item
  - Stinchcombe, Thomas E., Lydia Hodgson, James E. Herndon, Michael J. Kelley, M Giulia Cicchetti, Nithya Ramnath, Harvey B. Niell, et al. “Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.” J Thorac Oncol 4, no. 9 (September 2009): 1117–25. https://doi.org/10.1097/JTO.0b013e3181b27b33.
    Full Text Link to Item
  - Zafar, S Yousuf, Jennifer E. Marcello, Jane L. Wheeler, Krista L. Rowe, Michael A. Morse, James E. Herndon, and Amy P. Abernethy. “Longitudinal patterns of chemotherapy use in metastatic colorectal cancer.” J Oncol Pract 5, no. 5 (September 2009): 228–33. https://doi.org/10.1200/JOP.091010.
    Full Text Link to Item
  - Affronti, Mary Lou, Christopher R. Heery, James E. Herndon, Jeremy N. Rich, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Allan H. Friedman, Darell D. Bigner, and Henry S. Friedman. “Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.” Cancer 115, no. 15 (August 1, 2009): 3501–11. https://doi.org/10.1002/cncr.24398.
    Full Text Link to Item
  - Abernethy, Amy P., James E. Herndon, Jane L. Wheeler, Krista Rowe, Jennifer Marcello, and Meenal Patwardhan. “Poor documentation prevents adequate assessment of quality metrics in colorectal cancer.” J Oncol Pract 5, no. 4 (July 2009): 167–74. https://doi.org/10.1200/JOP.0942003.
    Full Text Link to Item
  - Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, and Henry S. Friedman. “Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.” Cancer 115, no. 13 (July 1, 2009): 2964–70. https://doi.org/10.1002/cncr.24336.
    Full Text Link to Item
  - Abernethy, Amy P., James E. Herndon, Jane L. Wheeler, Jeannette M. Day, Linda Hood, Meenal Patwardhan, Heather Shaw, and Herbert Kim Lyerly. “Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology.” J Pain Symptom Manage 37, no. 6 (June 2009): 1027–38. https://doi.org/10.1016/j.jpainsymman.2008.07.011.
    Full Text Link to Item
  - Abernethy, Amy P., Sally Y. Barbour, Hope Uronis, S Yousuf Zafar, April Coan, Krista Rowe, Mary Ruth Pupa, Jane L. Wheeler, and James E. Herndon. “Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center.” Support Care Cancer 17, no. 6 (June 2009): 735–44. https://doi.org/10.1007/s00520-008-0562-6.
    Full Text Link to Item
  - Friedman, D. R., A. H. Dupont, A. D. Coan, J. E. Herndon, K. L. Rowe, and A. P. Abernethy. “Survivorship care planning needs in diffuse large B-cell lymphoma (DLBCL).” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e20703.
    Link to Item
  - Heimberger, A. B., G. E. Archer, D. A. Mitchell, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, et al. “Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2021.
    Link to Item
  - Lyerly, H. K., T. Staley, J. E. Herndon, A. Coan, J. L. Wheeler, K. Rowe, B. Horne, and A. P. Abernethy. “Impact of a psychosocial intervention on performance status and coping.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 9611.
    Link to Item
  - Peters, K., A. Desjardins, D. A. Reardon, S. Perry, J. E. Herndon, L. Bailey, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. J. Vredenburgh. “Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM).” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e13025.
    Link to Item
  - Sampson, J. H., G. E. Archer, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, H. S. Friedman, T. Keler, D. A. Reardon, and D. A. Mitchell. “Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2034.
    Link to Item
  - Stinchcombe, T. E., L. Hodgson, J. E. Herndon, M. J. Kelley, M. Cicchetti, N. Ramnath, H. B. Niell, J. N. Atkins, M. R. Green, and E. E. Vokes. “Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 7535.
    Link to Item
  - Vredenburgh, J. J., A. Desjardins, D. A. Reardon, K. Peters, J. E. Herndon, J. Kirkpatrick, S. Gururangan, L. Bailey, A. H. Friedman, and H. S. Friedman. “Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM).” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 2015.
    Link to Item
  - Reardon, David A., Merrill J. Egorin, Annick Desjardins, James J. Vredenburgh, Jan H. Beumer, Theodore F. Lagattuta, Sridharan Gururangan, James E. Herndon, August J. Salvado, and Henry S. Friedman. “Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.” Cancer 115, no. 10 (May 15, 2009): 2188–98. https://doi.org/10.1002/cncr.24213.
    Full Text Link to Item
  - Dupont, Alexandra, Jane Wheeler, James E. Herndon, April Coan, S Yousuf Zafar, Linda Hood, Meenal Patwardhan, Heather S. Shaw, H Kim Lyerly, and Amy P. Abernethy. “Use of tablet personal computers for sensitive patient-reported information.” J Support Oncol 7, no. 3 (May 2009): 91–97.
    Link to Item
  - Strauss, G. M., J. E. Herndon, M. A. Maddaus, R. L. Schilsky, E. E. Vokes, and M. R. Green. “Reply to A. Katz et al.” Journal of Clinical Oncology 27, no. 13 (May 1, 2009): 2301–2. https://doi.org/10.1200/JCO.2008.21.2126.
    Full Text
  - Kuan, Chien-Tsun, Kenji Wakiya, James E. Herndon, Carol J. Wikstrand, Roger E. McLendon, Michael R. Zalutsky, Ira H. Pastan, and Darell D. Bigner. “RECOMBINANT ANTIBODY-BASED MOLECULAR THERAPEUTICS FOR BRAIN TUMOR IMMUNOTHERAPY.” Neuro Oncology 11, no. 2 (April 1, 2009): 224–224.
    Link to Item
  - Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, et al. “Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.” J Clin Oncol 27, no. 8 (March 10, 2009): 1262–67. https://doi.org/10.1200/JCO.2008.18.8417.
    Full Text Link to Item
  - Paskett, Electra, James Herndon, Kathleen Donohue, Michelle Naughton, Stephen Grubbs, Michael Pavy, Martee Hensley, et al. “Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541.” Cancer 115, no. 5 (March 1, 2009): 1109–20. https://doi.org/10.1002/cncr.24140.
    Full Text Link to Item
  - Yan, Hai, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, et al. “IDH1 and IDH2 mutations in gliomas.” N Engl J Med 360, no. 8 (February 19, 2009): 765–73. https://doi.org/10.1056/NEJMoa0808710.
    Full Text Link to Item
  - Alfano, Catherine M., Jeannette M. Day, Mira L. Katz, James E. Herndon, Marisa A. Bittoni, Jill M. Oliveri, Kathleen Donohue, and Electra D. Paskett. “Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804.” Psychooncology 18, no. 2 (February 2009): 128–33. https://doi.org/10.1002/pon.1378.
    Full Text Link to Item
  - Birchard, Katherine R., Jenny K. Hoang, James E. Herndon, and Edward F. Patz. “Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival.” Cancer 115, no. 3 (February 1, 2009): 581–86. https://doi.org/10.1002/cncr.24060.
    Full Text Link to Item
  - Katz, Mira L., Kathleen A. Donohue, Catherine M. Alfano, Jeannette M. Day, James E. Herndon, and Electra D. Paskett. “Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer. Cancer and Leukemia Group B 79804.” Cancer 115, no. 3 (February 1, 2009): 480–88. https://doi.org/10.1002/cncr.24063.
    Full Text Link to Item
  - Quinn, Jennifer A., Sara Xiaoyin Jiang, James Carter, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, et al. “Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.” Clin Cancer Res 15, no. 3 (February 1, 2009): 1064–68. https://doi.org/10.1158/1078-0432.CCR-08-2130.
    Full Text Link to Item
  - Abernethy, Amy P., James E. Herndon, Jane L. Wheeler, Meenal Patwardhan, Heather Shaw, H Kim Lyerly, and Kevin Weinfurt. “Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data.” Health Serv Res 43, no. 6 (December 2008): 1975–91. https://doi.org/10.1111/j.1475-6773.2008.00887.x.
    Full Text Link to Item
  - Oliveri, Jill M., Jeannette M. Day, Catherine M. Alfano, James E. Herndon, Mira L. Katz, Marisa A. Bittoni, Kathleen Donohue, and Electra D. Paskett. “Arm/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804.” J Cancer Surviv 2, no. 4 (December 2008): 233–42. https://doi.org/10.1007/s11764-008-0065-y.
    Full Text Link to Item
  - Schmittling, Robert J., Gary E. Archer, Duane A. Mitchell, Amy Heimberger, Charles Pegram, James E. Herndon, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.” J Immunol Methods 339, no. 1 (November 30, 2008): 74–81. https://doi.org/10.1016/j.jim.2008.08.004.
    Full Text Link to Item
  - Yousuf, S. Y., A. P. Abernethy, D. H. Abbott, S. C. Grambow, J. E. Marcello, J. E. Herndon, K. L. Rowe, et al. “Comorbidity, age, race and stage at diagnosis in colorectal cancer: A retrospective, parallel analysis of two health systems.” Bmc Cancer 8 (November 25, 2008). https://doi.org/10.1186/1471-2407-8-345.
    Full Text
  - Zafar, S Yousuf, Amy P. Abernethy, David H. Abbott, Steven C. Grambow, Jennifer E. Marcello, James E. Herndon, Krista L. Rowe, et al. “Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems.” Bmc Cancer 8 (November 25, 2008): 345. https://doi.org/10.1186/1471-2407-8-345.
    Full Text Open Access Copy Link to Item
  - Desjardins, Annick, David A. Reardon, James E. Herndon, Jennifer Marcello, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, et al. “Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.” Clin Cancer Res 14, no. 21 (November 1, 2008): 7068–73. https://doi.org/10.1158/1078-0432.CCR-08-0260.
    Full Text Link to Item
  - Paskett, Electra D., James E. Herndon, Jeannette M. Day, Nancy N. Stark, Eric P. Winer, Stephen S. Grubbs, Michael D. Pavy, et al. “Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.” Psychooncology 17, no. 11 (November 2008): 1108–20. https://doi.org/10.1002/pon.1329.
    Full Text Link to Item
  - Stinchcombe, Thomas E., Ann M. Mauer, Lydia D. Hodgson, James E. Herndon, Thomas J. Lynch, Mark R. Green, Everett E. Vokes, and Everett E. Cancer and Leukemia Group B. “Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.” J Thorac Oncol 3, no. 11 (November 2008): 1301–7. https://doi.org/10.1097/JTO.0b013e318187494a.
    Full Text Link to Item
  - Strauss, Gary M., James E. Herndon, Michael A. Maddaus, David W. Johnstone, Elizabeth A. Johnson, David H. Harpole, Heidi H. Gillenwater, et al. “Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.” J Clin Oncol 26, no. 31 (November 1, 2008): 5043–51. https://doi.org/10.1200/JCO.2008.16.4855.
    Full Text Link to Item
  - Bogart, Jeffrey A., Dorothy Watson, Edward F. McClay, Lisa Evans, James E. Herndon, Frances Laurie, Stephen L. Seagren, T. J. Fitzgerald, Everett Vokes, and Mark R. Green. “Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235.” Lung Cancer 62, no. 1 (October 2008): 92–98. https://doi.org/10.1016/j.lungcan.2008.02.006.
    Full Text Link to Item
  - Burfeind, William R., Betty C. Tong, Erin O’Branski, James E. Herndon, Eric M. Toloza, Thomas A. D’Amico, Linda H. Harpole, and David H. Harpole. “Quality of life outcomes are equivalent after lobectomy in the elderly.” J Thorac Cardiovasc Surg 136, no. 3 (September 2008): 597–604. https://doi.org/10.1016/j.jtcvs.2008.02.093.
    Full Text Link to Item
  - Herndon, James E., Alice B. Kornblith, Jimmie C. Holland, and Electra D. Paskett. “Patient education level as a predictor of survival in lung cancer clinical trials.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 25 (September 2008): 4116–23. https://doi.org/10.1200/jco.2008.16.7460.
    Full Text
  - Greenberg, Jacob A., David Shibata, James E. Herndon, Glenn D. Steele, Robert Mayer, and Ronald Bleday. “Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.” Dis Colon Rectum 51, no. 8 (August 2008): 1185–91. https://doi.org/10.1007/s10350-008-9231-6.
    Full Text Link to Item
  - Reardon, David A., Annick Desjardins, James J. Vredenburgh, Sith Sathornsumetee, Jeremy N. Rich, Jennifer A. Quinn, Theodore F. Lagattuta, et al. “Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.” Neuro Oncol 10, no. 3 (June 2008): 330–40. https://doi.org/10.1215/15228517-2008-003.
    Full Text Link to Item
  - Sampson, John H., Gamal Akabani, Gerald E. Archer, Mitchel S. Berger, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, et al. “Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.” Neuro Oncol 10, no. 3 (June 2008): 320–29. https://doi.org/10.1215/15228517-2008-012.
    Full Text Link to Item
  - Abernethy, A. P., Y. Zafar, J. Marcello, J. Wheeler, K. Rowe, M. A. Morse, and J. E. Herndon. “Treatment-related toxicity and supportive care in metastatic colorectal cancer (mCRC).” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 15087.
    Link to Item
  - Abernethy, A. P., Y. Zafar, J. Marcello, J. Wheeler, K. Rowe, M. A. Morse, and J. E. Herndon. “Treatment-related toxicity and supportive care in metastatic colorectal cancer (mCRC).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 15087–15087. https://doi.org/10.1200/jco.2008.26.15_suppl.15087.
    Full Text
  - Desjardins, A., D. P. Barboriak, J. E. Herndon, J. Marcello, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, H. S. Friedman, and J. J. Vredenburgh. “Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2026–2026. https://doi.org/10.1200/jco.2008.26.15_suppl.2026.
    Full Text
  - Garst, J., M. Datto, J. E. Herndon, W. T. Barry, D. Shoemaker, A. Bjurstrom, C. Andrews, G. Ginsburg, J. R. Nevins, and A. Potti. “A phase II prospective study evaluating the role of pemetrexed plus gemcitabine (Pem/Gem) chemotherapy as intial treatment in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) using a genomic predictor of cisplatin-resistance to guide therapy.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 8108–8108. https://doi.org/10.1200/jco.2008.26.15_suppl.8108.
    Full Text
  - Herndon, J. E., Y. Zafar, J. Marcello, J. Wheeler, K. Rowe, M. A. Morse, and A. P. Abernethy. “Longitudinal patterns of chemotherapy (CT) use in metastatic colorectal cancer (mCRC).” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 15082.
    Link to Item
  - Herndon, J. E., Y. Zafar, J. Marcello, J. Wheeler, K. Rowe, M. A. Morse, and A. P. Abernethy. “Longitudinal patterns of chemotherapy (CT) use in metastatic colorectal cancer (mCRC).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 15082–15082. https://doi.org/10.1200/jco.2008.26.15_suppl.15082.
    Full Text
  - Mitchell, D., G. E. Archer, D. D. Bigner, H. S. Friedman, D. Lally-Goss, J. E. Herndon, S. McGehee, R. McLendon, D. A. Reardon, and J. H. Sampson. “Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM.” Journal of Clinical Oncology 26, no. 15 (May 20, 2008).
    Link to Item
  - Scheri, R. P., J. E. Herndon, J. Marcello, J. Wheeler, D. S. Tyler, and A. P. Abernethy. “Mortality burden of melanoma: Metastatic site-specific and temporal trends.” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 9076.
    Link to Item
  - Uronis, H. E., J. E. Herndon, A. Coan, K. Bronson, J. Wheeler, H. K. Lyerly, M. A. Morse, and A. P. Abernethy. “E/Tablets to collect research-quality, patient-reported data.” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 17528.
    Link to Item
  - Wagner, S. A., A. Desjardins, D. A. Reardon, J. Marcello, J. E. Herndon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, H. S. Friedman, and J. J. Vredenburgh. “Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2021–2021. https://doi.org/10.1200/jco.2008.26.15_suppl.2021.
    Full Text
  - Arnold, Staci D., Leslie M. Forman, Bart D. Brigidi, Karen E. Carter, Holly A. Schweitzer, Heather E. Quinn, A Bebe Guill, James E. Herndon, and Renee H. Raynor. “Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors.” Neuro Oncol 10, no. 2 (April 2008): 171–81. https://doi.org/10.1215/15228517-2007-057.
    Full Text Link to Item
  - Reardon, David A., Michael R. Zalutsky, Gamal Akabani, R Edward Coleman, Allan H. Friedman, James E. Herndon, Roger E. McLendon, et al. “A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.” Neuro Oncol 10, no. 2 (April 2008): 182–89. https://doi.org/10.1215/15228517-2007-053.
    Full Text Link to Item
  - Hoang, Jenny K., Luke F. Hoagland, R Edward Coleman, April D. Coan, James E. Herndon, and Edward F. Patz. “Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.” J Clin Oncol 26, no. 9 (March 20, 2008): 1459–64. https://doi.org/10.1200/JCO.2007.14.3628.
    Full Text Link to Item
  - Lamont, Elizabeth B., James E. Herndon, Jane C. Weeks, I Craig Henderson, Rogerio Lilenbaum, Richard L. Schilsky, Nicholas A. Christakis, and Nicholas A. Cancer and Leukemia Group B. “Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.” Med Care 46, no. 3 (March 2008): 303–8. https://doi.org/10.1097/MLR.0b013e31815cecc3.
    Full Text Link to Item
  - Graziano, Stephen L., James E. Herndon, Mark A. Socinski, Xiaofei Wang, Dorothy Watson, Everett Vokes, Mark R. Green, and Mark R. Cancer and Leukemia Group B. “Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.” J Thorac Oncol 3, no. 2 (February 2008): 158–62. https://doi.org/10.1097/JTO.0b013e318161225e.
    Full Text Link to Item
  - Sathornsumetee, Sith, Yiting Cao, Jennifer E. Marcello, James E. Herndon, Roger E. McLendon, Annick Desjardins, Henry S. Friedman, Mark W. Dewhirst, James J. Vredenburgh, and Jeremy N. Rich. “Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.” J Clin Oncol 26, no. 2 (January 10, 2008): 271–78. https://doi.org/10.1200/JCO.2007.13.3652.
    Full Text Link to Item
  - Ochiai, Hidenobu, Gary E. Archer, James E. Herndon, Chien-Tsun Kuan, Duane A. Mitchell, Darell D. Bigner, Ira H. Pastan, and John H. Sampson. “EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.” Cancer Immunol Immunother 57, no. 1 (January 2008): 115–21. https://doi.org/10.1007/s00262-007-0363-7.
    Full Text Link to Item
  - Patz, Edward F., Michael J. Campa, Elizabeth B. Gottlin, Irina Kusmartseva, Xiang Rong Guan, and James E. Herndon. “Panel of serum biomarkers for the diagnosis of lung cancer.” J Clin Oncol 25, no. 35 (December 10, 2007): 5578–83. https://doi.org/10.1200/JCO.2007.13.5392.
    Full Text Link to Item
  - Hoagland, Luke F. M., Michael J. Campa, Elizabeth B. Gottlin, James E. Herndon, and Edward F. Patz. “Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer.” Cancer 110, no. 10 (November 15, 2007): 2260–68. https://doi.org/10.1002/cncr.23049.
    Full Text Link to Item
  - Swanson, Scott J., James E. Herndon, Thomas A. D’Amico, Todd L. Demmy, Robert J. McKenna, Mark R. Green, and David J. Sugarbaker. “Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study.” J Clin Oncol 25, no. 31 (November 1, 2007): 4993–97. https://doi.org/10.1200/JCO.2007.12.6649.
    Full Text Link to Item
  - Vredenburgh, James J., Annick Desjardins, James E. Herndon, Jennifer Marcello, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, et al. “Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.” J Clin Oncol 25, no. 30 (October 20, 2007): 4722–29. https://doi.org/10.1200/JCO.2007.12.2440.
    Full Text Link to Item
  - Linardic, Corinne M., Sarasija Naini, James E. Herndon, Chimen Kesserwan, Stephen J. Qualman, and Christopher M. Counter. “The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.” Cancer Res 67, no. 14 (July 15, 2007): 6691–99. https://doi.org/10.1158/0008-5472.CAN-06-3210.
    Full Text Link to Item
  - Loewen, Gregory M., Dorothy Watson, Leslie Kohman, James E. Herndon, Hani Shennib, Kemp Kernstine, Jemi Olak, et al. “Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238.” J Thorac Oncol 2, no. 7 (July 2007): 619–25. https://doi.org/10.1097/JTO.0b013e318074bba7.
    Full Text Link to Item
  - Sampson, John H., Raghu Raghavan, Martin L. Brady, James M. Provenzale, James E. Herndon, David Croteau, Allan H. Friedman, et al. “Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.” Neuro Oncol 9, no. 3 (July 2007): 343–53. https://doi.org/10.1215/15228517-2007-007.
    Full Text Link to Item
  - Gauger, Joerg, Edward F. Patz, R Edward Coleman, and James E. Herndon. “Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.” J Thorac Oncol 2, no. 6 (June 2007): 499–505. https://doi.org/10.1097/JTO.0b013e3180600990.
    Full Text Link to Item
  - Riedel, Richard F., Carolyn Andrews, Jennifer Garst, Frank Dunphy, James E. Herndon, Susan Blackwell, Sally Barbour, and Jeffrey Crawford. “A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.” J Thorac Oncol 2, no. 6 (June 2007): 520–25. https://doi.org/10.1097/JTO.0b013e318060107c.
    Full Text Link to Item
  - Desjardins, Annick, Jennifer A. Quinn, James J. Vredenburgh, Sith Sathornsumetee, Allan H. Friedman, James E. Herndon, Roger E. McLendon, et al. “Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.” J Neurooncol 83, no. 1 (May 2007): 53–60. https://doi.org/10.1007/s11060-006-9302-2.
    Full Text Link to Item
  - McLendon, Roger E., Gamal Akabani, Henry S. Friedman, David A. Reardon, Linda Cleveland, Ilkcan Cokgor, James E. Herndon, et al. “Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.” Nucl Med Biol 34, no. 4 (May 2007): 405–13. https://doi.org/10.1016/j.nucmedbio.2007.01.009.
    Full Text Link to Item
  - Vokes, Everett E., James E. Herndon, Michael J. Kelley, M Giulia Cicchetti, Nithya Ramnath, Harvey Neill, James N. Atkins, et al. “Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.” J Clin Oncol 25, no. 13 (May 1, 2007): 1698–1704. https://doi.org/10.1200/JCO.2006.07.3569.
    Full Text Link to Item
  - Cornett, W. R., L. M. McCall, R. P. Petersen, J. E. Herndon, and D. S. Tyler. “In reply [8].” Journal of Clinical Oncology 25, no. 11 (April 10, 2007): 1450–51. https://doi.org/10.1200/JCO.2006.10.4331.
    Full Text
  - Gururangan, Sridharan, Michael J. Fisher, Jeffrey C. Allen, James E. Herndon, Jennifer A. Quinn, David A. Reardon, James J. Vredenburgh, et al. “Temozolomide in children with progressive low-grade glioma.” Neuro Oncol 9, no. 2 (April 2007): 161–68. https://doi.org/10.1215/15228517-2006-030.
    Full Text Link to Item
  - Cornett, W. R., L. M. McCall, R. P. Petersen, J. E. Herndon, and D. S. Tyler. “In reply [14].” Journal of Clinical Oncology 25, no. 9 (March 20, 2007): 1149–51. https://doi.org/10.1200/JCO.2006.09.9440.
    Full Text
  - Vredenburgh, James J., Annick Desjardins, James E. Herndon, Jeannette M. Dowell, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, et al. “Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.” Clin Cancer Res 13, no. 4 (February 15, 2007): 1253–59. https://doi.org/10.1158/1078-0432.CCR-06-2309.
    Full Text Link to Item
  - Rocha-Lima, C. M., J. E. Herndon, M. E. Lee, J. N. Atkins, A. Mauer, E. Vokes, M. R. Green, and M. R. Cancer and Leukemia Group B. “Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.” Ann Oncol 18, no. 2 (February 2007): 331–37. https://doi.org/10.1093/annonc/mdl375.
    Full Text Link to Item
  - Badruddoja, Michael A., Kara Penne, Annick Desjardins, David A. Reardon, Jeremy N. Rich, Jennifer A. Quinn, Sith Sathornsumetee, et al. “Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.” Neuro Oncol 9, no. 1 (January 2007): 70–74. https://doi.org/10.1215/15228517-2006-022.
    Full Text Link to Item
  - Jaklitsch, Michael T., James E. Herndon, Malcolm M. DeCamp, William G. Richards, Parvesh Kumar, Mark J. Krasna, Mark R. Green, and David J. Sugarbaker. “Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.” J Surg Oncol 94, no. 7 (December 1, 2006): 599–606. https://doi.org/10.1002/jso.20644.
    Full Text Link to Item
  - Kornblith, Alice B., Jeannette M. Dowell, James E. Herndon, Beverly J. Engelman, Susan Bauer-Wu, Eric J. Small, Vicki A. Morrison, James Atkins, Harvey Jay Cohen, and Jimmie C. Holland. “Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study.” Cancer 107, no. 11 (December 1, 2006): 2706–14. https://doi.org/10.1002/cncr.22296.
    Full Text Link to Item
  - Riedel, Richard F., Jeffrey Crawford, Frank Dunphy, James E. Herndon, Jennifer Garst, and Michael J. Kelley. “Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.” Lung Cancer 54, no. 3 (December 2006): 431–32. https://doi.org/10.1016/j.lungcan.2006.08.008.
    Full Text Link to Item
  - Vlahovic, G., Z. N. Rabbani, J. E. Herndon, M. W. Dewhirst, and Z. Vujaskovic. “Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.” Br J Cancer 95, no. 8 (October 23, 2006): 1013–19. https://doi.org/10.1038/sj.bjc.6603366.
    Full Text Open Access Copy Link to Item
  - Anscher, Mitchell S., Jennifer Garst, Lawrence B. Marks, Nicole Larrier, Frank Dunphy, James E. Herndon, Robert Clough, et al. “Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.” Int J Radiat Oncol Biol Phys 66, no. 2 (October 1, 2006): 477–82. https://doi.org/10.1016/j.ijrobp.2006.05.031.
    Full Text Link to Item
  - Maxwell, Jill A., Stewart P. Johnson, Jennifer A. Quinn, Roger E. McLendon, Francis Ali-Osman, Allan H. Friedman, James E. Herndon, et al. “Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.” Mol Cancer Ther 5, no. 10 (October 2006): 2531–39. https://doi.org/10.1158/1535-7163.MCT-06-0106.
    Full Text Link to Item
  - Cornett, Wendy R., Linda M. McCall, Rebecca P. Petersen, Merrick I. Ross, Henry A. Briele, R Dirk Noyes, Jeffrey J. Sussman, et al. “Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.” J Clin Oncol 24, no. 25 (September 1, 2006): 4196–4201. https://doi.org/10.1200/JCO.2005.05.5152.
    Full Text Link to Item
  - Lamont, Elizabeth B., James E. Herndon, Jane C. Weeks, I Craig Henderson, Craig C. Earle, Richard L. Schilsky, Nicholas A. Christakis, and Nicholas A. Cancer and Leukemia Group B. “Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).” Journal of the National Cancer Institute 98, no. 18 (September 2006): 1335–38. https://doi.org/10.1093/jnci/djj363.
    Full Text Open Access Copy
  - Reardon, D. A., M. R. Zalutsky, G. Akabani, R. E. Coleman, A. H. Friedman, R. E. McLendon, H. S. Friedman, J. E. Herndon, J. Kirkpatrick, and D. D. Bigner. “Radioimmunotherapy of patients with malignant brain tumors: patient-specific dosing of I-131-labeled anti-tenacin antibody to achieve 44 Gy boost dose to resection cavity margins.” European Journal of Nuclear Medicine and Molecular Imaging 33 (September 1, 2006): S194–S194.
    Link to Item
  - Zalutsky, M. R., D. A. Reardon, J. A. Quinn, R. E. Coleman, G. Akabani, A. H. Friedman, H. S. Friedman, et al. “Chimeric murine/human IgG(2) anti-tenascin 81C6 monoclonal antibody: phase I trial in patients with malignant glioma of a construct with improved stability.” European Journal of Nuclear Medicine and Molecular Imaging 33 (September 1, 2006): S194–S194.
    Link to Item
  - Strauss, G. M., J. E. Herndon, M. A. Maddaus, D. W. Johnstone, E. A. Johnson, D. M. Watson, D. J. Sugarbaker, et al. “Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 7007.
    Link to Item
  - Vredenburgh, J. J., A. Desjardins, J. E. Herndon, J. Quinn, J. Rich, S. Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, and A. Friedman. “Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.” J Clin Oncol 24, no. 18_suppl (June 20, 2006): 1506.
    Link to Item
  - D’Amico, Thomas A., Kelli R. Brooks, Mary-Beth Moore Joshi, Debbi Conlon, James Herndon, Rebecca P. Petersen, and David H. Harpole. “Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.” Ann Thorac Surg 81, no. 6 (June 2006): 1982–87. https://doi.org/10.1016/j.athoracsur.2006.01.042.
    Full Text Link to Item
  - Reardon, David A., Jennifer A. Quinn, Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, et al. “Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.” J Nucl Med 47, no. 6 (June 2006): 912–18.
    Link to Item
  - Kuan, Chien-Tsun, Kenji Wakiya, Jeannette M. Dowell, James E. Herndon, David A. Reardon, Michael W. Graner, Gregory J. Riggins, Carol J. Wikstrand, and Darell D. Bigner. “Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.” Clin Cancer Res 12, no. 7 Pt 1 (April 1, 2006): 1970–82. https://doi.org/10.1158/1078-0432.CCR-05-2797.
    Full Text Link to Item
  - Wilke, Lee Gravatt, Linda M. McCall, Katherine E. Posther, Pat W. Whitworth, Douglas S. Reintgen, A Marilyn Leitch, Sheryl G. A. Gabram, et al. “Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial.” Ann Surg Oncol 13, no. 4 (April 2006): 491–500. https://doi.org/10.1245/ASO.2006.05.013.
    Full Text Link to Item
  - Kemeny, Nancy E., Donna Niedzwiecki, Donna R. Hollis, Heinz-Josef Lenz, Robert S. Warren, Michelle J. Naughton, Jane C. Weeks, et al. “Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).” J Clin Oncol 24, no. 9 (March 20, 2006): 1395–1403. https://doi.org/10.1200/JCO.2005.03.8166.
    Full Text Link to Item
  - Fecci, Peter E., Duane A. Mitchell, John F. Whitesides, Weihua Xie, Allan H. Friedman, Gary E. Archer, James E. Herndon, Darell D. Bigner, Glenn Dranoff, and John H. Sampson. “Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.” Cancer Res 66, no. 6 (March 15, 2006): 3294–3302. https://doi.org/10.1158/0008-5472.CAN-05-3773.
    Full Text Link to Item
  - Allen, Mark S., Gail E. Darling, Taine T. V. Pechet, John D. Mitchell, James E. Herndon, Rodney J. Landreneau, Richard I. Inculet, et al. “Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial.” Ann Thorac Surg 81, no. 3 (March 2006): 1013–19. https://doi.org/10.1016/j.athoracsur.2005.06.066.
    Full Text Link to Item
  - Kornblith, A. B., J. M. Dowell, J. E. Herndon, S. Rosenberg, B. Engelman, E. J. Small, V. A. Morrison, J. Atkins, H. Muss, and J. C. Holland. “Telephone monitoring: Early identification of psychological, physical and social distress in older advanced-stage cancer patients.” Psycho Oncology 15, no. 1 (February 1, 2006): S21–22.
    Link to Item
  - Reardon, David A., Jennifer A. Quinn, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, Annick Desjardins, Sith Sathornsumetee, et al. “Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.” Clin Cancer Res 12, no. 3 Pt 1 (February 1, 2006): 860–68. https://doi.org/10.1158/1078-0432.CCR-05-2215.
    Full Text Link to Item
  - Blackstock, A William, James E. Herndon, Electra D. Paskett, Antonius A. Miller, Christopher Lathan, Harvey B. Niell, Mark A. Socinski, Everett E. Vokes, Mark R. Green, and Mark R. Cancer and Leukemia Group B. “Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B.” J Clin Oncol 24, no. 3 (January 20, 2006): 407–12. https://doi.org/10.1200/JCO.2005.02.1436.
    Full Text Link to Item
  - Garst, Jennifer, James E. Herndon, Timothy Shafman, Lara Campagna, Susan Blackwell, Karen Padilla, Toni Bjurstrom, et al. “A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.” Clin Drug Investig 26, no. 5 (2006): 257–66. https://doi.org/10.2165/00044011-200626050-00003.
    Full Text Link to Item
  - Reardon, David A., Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Roger E. McLendon, et al. “Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.” J Clin Oncol 24, no. 1 (January 1, 2006): 115–22. https://doi.org/10.1200/JCO.2005.03.4082.
    Full Text Link to Item
  - Reardon, David A., Merrill J. Egorin, Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James J. Vredenburgh, Annick Desjardins, et al. “Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.” J Clin Oncol 23, no. 36 (December 20, 2005): 9359–68. https://doi.org/10.1200/JCO.2005.03.2185.
    Full Text Link to Item
  - Patz, E. F., S. J. Swensen, and J. E. Herndon. “In reply [4].” Journal of Clinical Oncology 23, no. 9 (December 1, 2005): 2107–8. https://doi.org/10.1200/JCO.2005.05.267.
    Full Text
  - Patz, E. F., S. J. Swensen, and J. E. Herndon. “In reply [12].” Journal of Clinical Oncology 23, no. 10 (December 1, 2005): 2440–41. https://doi.org/10.1200/JCO.2005.05.230.
    Full Text
  - Weeks, J. C., D. Romanus, J. E. Herndon, D. Schrag, R. J. Mayer, and N. Kemeny. “PCN13 COST-EFFECTIVENESS OF HEPATIC ARTERY INFUSION FOR METASTATIC COLORECTAL CANCER (CALGB 9481).” Value in Health 8, no. 6 (November 2005): A37–A37. https://doi.org/10.1016/s1098-3015(10)67251-8.
    Full Text
  - McLendon, Roger E., James E. Herndon, Bryan West, David Reardon, Rodney Wiltshire, BK Ahmed Rasheed, Jennifer Quinn, Henry S. Friedman, Allan H. Friedman, and Darell D. Bigner. “Survival analysis of presumptive prognostic markers among oligodendrogliomas.” Cancer 104, no. 8 (October 15, 2005): 1693–99. https://doi.org/10.1002/cncr.21362.
    Full Text Link to Item
  - Peppercorn, Jeffrey, James Herndon, Alice B. Kornblith, William Peters, Tim Ahles, James Vredenburgh, Gary Schwartz, et al. “Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.” Cancer 104, no. 8 (October 15, 2005): 1580–89. https://doi.org/10.1002/cncr.21363.
    Full Text Link to Item
  - Leitch, A Marilyn, Peter D. Beitsch, Linda M. McCall, Katherine Posther, Lisa A. Newman, James E. Herndon, Kelly K. Hunt, and Armando E. Giuliano. “Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer.” Am J Surg 190, no. 4 (October 2005): 539–42. https://doi.org/10.1016/j.amjsurg.2005.06.024.
    Full Text Link to Item
  - Posther, Katherine E., Linda M. McCall, Peter W. Blumencranz, William E. Burak, Peter D. Beitsch, Nora M. Hansen, Monica Morrow, et al. “Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer.” Ann Surg 242, no. 4 (October 2005): 593–99. https://doi.org/10.1097/01.sla.0000184210.68646.77.
    Full Text Link to Item
  - Quinn, Jennifer A., Annick Desjardins, Jon Weingart, Henry Brem, M Eileen Dolan, Shannon M. Delaney, James Vredenburgh, et al. “Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.” J Clin Oncol 23, no. 28 (October 1, 2005): 7178–87. https://doi.org/10.1200/JCO.2005.06.502.
    Full Text Link to Item
  - Reardon, David A., Jennifer A. Quinn, Jeremy N. Rich, Annick Desjardins, James Vredenburgh, Sridharan Gururangan, Sith Sathornsumetee, et al. “Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.” Cancer 104, no. 7 (October 1, 2005): 1478–86. https://doi.org/10.1002/cncr.21316.
    Full Text Link to Item
  - Lamont, Elizabeth B., James E. Herndon, Jane C. Weeks, I Craig Henderson, Rogerio Lilenbaum, Richard L. Schilsky, and Nicholas A. Christakis. “Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.” J Natl Cancer Inst 97, no. 14 (July 20, 2005): 1080–83. https://doi.org/10.1093/jnci/dji189.
    Full Text Link to Item
  - Akerley, Wallace, James E. Herndon, Alan P. Lyss, Hak Choy, Andrew Turrisi, Stephen Graziano, Todd Williams, Chunfeng Zhang, Everett E. Vokes, and Mark R. Green. “Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.” Clin Lung Cancer 7, no. 1 (July 2005): 47–53. https://doi.org/10.3816/CLC.2005.n.021.
    Full Text Link to Item
  - Kindler, Hedy L., James E. Herndon, Chunfeng Zhang, Mark R. Green, and Mark R. Cancer and Leukemia Group B. “Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.” Lung Cancer 48, no. 3 (June 2005): 423–28. https://doi.org/10.1016/j.lungcan.2004.12.002.
    Full Text Link to Item
  - Miller, Antonius A., James E. Herndon, Lin Gu, Mark R. Green, and Mark R. Cancer and Leukemia Group B. “Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).” Lung Cancer 48, no. 3 (June 2005): 399–407. https://doi.org/10.1016/j.lungcan.2004.11.019.
    Full Text Link to Item
  - Niell, Harvey B., James E. Herndon, Antonius A. Miller, Dorothy M. Watson, Alan B. Sandler, Karen Kelly, Randolph S. Marks, et al. “Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.” J Clin Oncol 23, no. 16 (June 1, 2005): 3752–59. https://doi.org/10.1200/JCO.2005.09.071.
    Full Text Link to Item
  - D’Cunha, Jonathan, James E. Herndon, Debra L. Herzan, G Alexander Patterson, Leslie J. Kohman, David H. Harpole, Kemp H. Kernstine, et al. “Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial.” Lung Cancer 48, no. 2 (May 2005): 241–46. https://doi.org/10.1016/j.lungcan.2004.11.006.
    Full Text Link to Item
  - Hensley, Martee L., Jeannette Dowell, James E. Herndon, Eric Winer, Nancy Stark, Jane C. Weeks, and Electra Paskett. “Economic outcomes of breast cancer survivorship: CALGB study 79804.” Breast Cancer Res Treat 91, no. 2 (May 2005): 153–61. https://doi.org/10.1007/s10549-004-6497-9.
    Full Text Link to Item
  - Clamon, Gerald, James Herndon, Jeffrey Kern, Ramaswamy Govindan, Jennifer Garst, Dorothy Watson, Mark Green, and Mark Cancer and Leukemia Group B. “Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.” Cancer 103, no. 8 (April 15, 2005): 1670–75. https://doi.org/10.1002/cncr.20950.
    Full Text Link to Item
  - Kelley, Michael J., Elizabeth M. Glaser, James E. Herndon, Frank Becker, Rajesh Bhagat, Yu-Jing Zhang, Regina M. Santella, et al. “Safety and efficacy of weekly oral oltipraz in chronic smokers.” Cancer Epidemiol Biomarkers Prev 14, no. 4 (April 2005): 892–99. https://doi.org/10.1158/1055-9965.EPI-04-0585.
    Full Text Link to Item
  - Kim, Yun-Hyeon, Edith M. Marom, James E. Herndon, and H Page McAdams. “Pulmonary vein diameter, cross-sectional area, and shape: CT analysis.” Radiology 235, no. 1 (April 2005): 43–49. https://doi.org/10.1148/radiol.2351032106.
    Full Text Link to Item
  - Shennib, Hani, Jeffrey Bogart, James E. Herndon, Leslie Kohman, Robert Keenan, Mark Green, David Sugarbaker, David Cancer and Leukemia Group B, and David Eastern Cooperative Oncology Group. “Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study.” J Thorac Cardiovasc Surg 129, no. 4 (April 2005): 813–18. https://doi.org/10.1016/j.jtcvs.2004.05.011.
    Full Text Link to Item
  - Govindan, Ramaswamy, Robert A. Kratzke, James E. Herndon, Gloria A. Niehans, Robin Vollmer, Dorothy Watson, Mark R. Green, Hedy L. Kindler, and Hedy L. Cancer and Leukemia Group B (CALGB 30101). “Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.” Clin Cancer Res 11, no. 6 (March 15, 2005): 2300–2304. https://doi.org/10.1158/1078-0432.CCR-04-1940.
    Full Text Link to Item
  - Joshi, Mary-Beth Moore, Yoshinori Shirota, Kathleen D. Danenberg, Debbi H. Conlon, Dennis S. Salonga, James E. Herndon, Peter V. Danenberg, and David H. Harpole. “High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.” Clin Cancer Res 11, no. 6 (March 15, 2005): 2215–21. https://doi.org/10.1158/1078-0432.CCR-04-1387.
    Full Text Link to Item
  - Dresler, Carolyn M., Jemi Olak, James E. Herndon, William G. Richards, Ernest Scalzetti, Stewart B. Fleishman, Kemp H. Kernstine, et al. “Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.” Chest 127, no. 3 (March 2005): 909–15. https://doi.org/10.1378/chest.127.3.909.
    Full Text
  - McClay, Edward F., Jeff Bogart, James E. Herndon, Dee Watson, Lisa Evans, Steven L. Seagren, Mark R. Green, and Mark R. Cancer and Leukemia Group B Study (9235). “A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).” Am J Clin Oncol 28, no. 1 (February 2005): 81–90. https://doi.org/10.1097/01.coc.0000139940.52625.d0.
    Full Text Link to Item
  - Reardon, David A., Jennifer A. Quinn, James Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, Michael Badruddoja, James E. Herndon, Jeannette M. Dowell, Allan H. Friedman, and Henry S. Friedman. “Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.” Cancer 103, no. 2 (January 15, 2005): 329–38. https://doi.org/10.1002/cncr.20776.
    Full Text Link to Item
  - Lilenbaum, Rogerio C., James E. Herndon, Marcy A. List, Chris Desch, Dorothy M. Watson, Antonius A. Miller, Stephen L. Graziano, et al. “Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).” J Clin Oncol 23, no. 1 (January 1, 2005): 190–96. https://doi.org/10.1200/JCO.2005.07.172.
    Full Text Link to Item
  - Gururangan, Sridharan, Eugene Hwang, James E. Herndon, Herbert Fuchs, Timothy George, and R Edward Coleman. “[18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma.” Neurosurgery 55, no. 6 (December 2004): 1280–88. https://doi.org/10.1227/01.neu.0000143027.41632.2b.
    Full Text Link to Item
  - Howard, Brandon A., Zhong Zheng, Michael J. Campa, Michael Z. Wang, Anupama Sharma, Eric Haura, James E. Herndon, Michael C. Fitzgerald, Gerold Bepler, and Edward F. Patz. “Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer.” Lung Cancer 46, no. 3 (December 2004): 313–23. https://doi.org/10.1016/j.lungcan.2004.05.013.
    Full Text Link to Item
  - Ahles, Tim A., James E. Herndon, Eric J. Small, Nicholas J. Vogelzang, Alice B. Kornblith, Mark J. Ratain, Walter Stadler, et al. “Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.” Cancer 101, no. 10 (November 15, 2004): 2202–8. https://doi.org/10.1002/cncr.20655.
    Full Text Link to Item
  - Marks, Lawrence B., Jennifer Garst, Mark A. Socinski, Gregory Sibley, A William Blackstock, James E. Herndon, Sunmin Zhou, et al. “Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.” J Clin Oncol 22, no. 21 (November 1, 2004): 4329–40. https://doi.org/10.1200/JCO.2004.02.165.
    Full Text Link to Item
  - Sherman, Carol A., James E. Herndon, Dorothy M. Watson, Mark R. Green, and Mark R. Cancer and Leukemia Group B. “A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer.” Lung Cancer 45, no. 3 (September 2004): 387–92. https://doi.org/10.1016/j.lungcan.2004.02.017.
    Full Text Link to Item
  - Wiltshire, Rodney N., James E. Herndon, Annie Lloyd, Henry S. Friedman, Darell D. Bigner, Sandra H. Bigner, and Roger E. McLendon. “Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.” J Mol Diagn 6, no. 3 (August 2004): 166–79. https://doi.org/10.1016/S1525-1578(10)60507-7.
    Full Text Link to Item
  - Vokes, E. E., J. E. Herndon, M. J. Kelley, D. Watson, M. G. Cicchetti, M. R. Green, and M. R. Cancer and Leukemia Group B. “Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 7005.
    Link to Item
  - Socinski, M. A., C. Zhang, J. E. Herndon, R. O. Dillman, G. Clamon, E. Vokes, W. Akerley, et al. “Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.” Ann Oncol 15, no. 7 (July 2004): 1033–41. https://doi.org/10.1093/annonc/mdh282.
    Full Text Link to Item
  - Bogart, Jeffrey A., James E. Herndon, Alan P. Lyss, Dorothy Watson, Antonius A. Miller, Michael E. Lee, Andrew T. Turrisi, Mark R. Green, and Mark R. Cancer and Leukemia Group B study 39808. “70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.” Int J Radiat Oncol Biol Phys 59, no. 2 (June 1, 2004): 460–68. https://doi.org/10.1016/j.ijrobp.2003.10.021.
    Full Text Link to Item
  - Cheran, Sendhil Kumar, James E. Herndon, and Edward F. Patz. “Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.” Lung Cancer 44, no. 3 (June 2004): 317–25. https://doi.org/10.1016/j.lungcan.2003.11.008.
    Full Text Link to Item
  - Patz, Edward F., Stephen J. Swensen, and James E. Herndon. “Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations.” J Clin Oncol 22, no. 11 (June 1, 2004): 2202–6. https://doi.org/10.1200/JCO.2004.12.046.
    Full Text Link to Item
  - McLendon, Roger E., Ahmed Rasheed, Rodney Wiltshire, and James Herndon. “Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma.” Mod Pathol 17, no. 5 (May 2004): 604–5. https://doi.org/10.1038/modpathol.3800077.
    Full Text Link to Item
  - Otterson, Gregory A., James E. Herndon, Dorothy Watson, Mark R. Green, Hedy L. Kindler, and Hedy L. Cancer and Leukemia Group B. “Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).” Lung Cancer 44, no. 2 (May 2004): 251–59. https://doi.org/10.1016/j.lungcan.2003.10.011.
    Full Text Link to Item
  - Quinn, Jennifer A., David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James Vredenburgh, Sridharan Gururangan, et al. “Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.” Neuro Oncol 6, no. 2 (April 2004): 145–53. https://doi.org/10.1215/S1152851703000498.
    Full Text Link to Item
  - Reardon, David A., Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James Vredenburgh, John H. Sampson, James M. Provenzale, et al. “Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.” Neuro Oncol 6, no. 2 (April 2004): 134–44. https://doi.org/10.1215/s1152851703000413.
    Full Text Link to Item
  - Marom, Edith M., James E. Herndon, Yun Hyeon Kim, and H Page McAdams. “Variations in pulmonary venous drainage to the left atrium: implications for radiofrequency ablation.” Radiology 230, no. 3 (March 2004): 824–29. https://doi.org/10.1148/radiol.2303030315.
    Full Text Link to Item
  - Rocha Lima, C. M., N. A. Rizvi, C. Zhang, J. E. Herndon, J. Crawford, R. Govindan, G. W. King, M. R. Green, and M. R. Cancer Leukemia Group B. “Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.” Ann Oncol 15, no. 3 (March 2004): 410–18. https://doi.org/10.1093/annonc/mdh104.
    Full Text Link to Item
  - Johnson, Elizabeth, Diana Lake, James E. Herndon, James W. Box, Thomas J. Lynch, and Mark R. Green. “Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332.” Am J Clin Oncol 27, no. 1 (February 2004): 19–23. https://doi.org/10.1097/01.coc.0000045850.98788.ed.
    Full Text Link to Item
  - Rich, Jeremy N., David A. Reardon, Terry Peery, Jeannette M. Dowell, Jennifer A. Quinn, Kara L. Penne, Carol J. Wikstrand, et al. “Phase II trial of gefitinib in recurrent glioblastoma.” J Clin Oncol 22, no. 1 (January 1, 2004): 133–42. https://doi.org/10.1200/JCO.2004.08.110.
    Full Text Link to Item
  - Vollmer, Robin T., James E. Herndon, Jonathan D’Cunha, Naif Z. Abraham, Joette Solberg, Mitra Fatourechi, Ann Maruska, et al. “Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761.” Clin Cancer Res 9, no. 15 (November 15, 2003): 5630–35.
    Link to Item
  - Bernacki, Susan H., Ana K. Stankovic, Laurina O. Williams, Jeanne C. Beck, James E. Herndon, Karen Snow-Bailey, Thomas W. Prior, et al. “Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing.” J Mol Diagn 5, no. 4 (November 2003): 227–30. https://doi.org/10.1016/S1525-1578(10)60478-3.
    Full Text Link to Item
  - Sampson, John H., Gamal Akabani, Gary E. Archer, Darell D. Bigner, Mitchel S. Berger, Allan H. Friedman, Henry S. Friedman, et al. “Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.” J Neurooncol 65, no. 1 (October 2003): 27–35. https://doi.org/10.1023/a:1026290315809.
    Full Text Link to Item
  - Kornblith, Alice B., James E. Herndon, Raymond B. Weiss, Chunfeng Zhang, Enid L. Zuckerman, Sylvia Rosenberg, Magriet Mertz, et al. “Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy.” Cancer 98, no. 4 (August 15, 2003): 679–89. https://doi.org/10.1002/cncr.11531.
    Full Text Link to Item
  - Anscher, Mitchell S., Lawrence B. Marks, Timothy D. Shafman, Robert Clough, Hong Huang, Andrea Tisch, Michael Munley, et al. “Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.” Int J Radiat Oncol Biol Phys 56, no. 4 (July 15, 2003): 988–95. https://doi.org/10.1016/s0360-3016(03)00184-6.
    Full Text Link to Item
  - Brooks, Kelli R., Kathleen To, Mary-Beth Moore Joshi, Debbi H. Conlon, James E. Herndon, Thomas A. D’Amico, and David H. Harpole. “Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.” Ann Thorac Surg 76, no. 1 (July 2003): 187–93. https://doi.org/10.1016/s0003-4975(03)00131-0.
    Full Text Link to Item
  - Marom, Edith M., Scott M. Palmer, Jeremy J. Erasmus, James E. Herndon, Chunfeng Zhang, and H Page McAdams. “Pleural effusions in lung transplant recipients: image-guided small-bore catheter drainage.” Radiology 228, no. 1 (July 2003): 241–45. https://doi.org/10.1148/radiol.2281020847.
    Full Text Link to Item
  - Gururangan, Sridharan, Colleen McLaughlin, Jennifer Quinn, Jeremy Rich, David Reardon, Edward C. Halperin, James Herndon, et al. “High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.” J Clin Oncol 21, no. 11 (June 1, 2003): 2187–91. https://doi.org/10.1200/JCO.2003.10.096.
    Full Text Link to Item
  - Akerley, Wallace, James E. Herndon, Merrill J. Egorin, Alan P. Lyss, Hedy L. Kindler, Dianne M. Savarese, Carol A. Sherman, et al. “Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.” Cancer 97, no. 10 (May 15, 2003): 2480–86. https://doi.org/10.1002/cncr.11375.
    Full Text Link to Item
  - Quinn, Jennifer A., David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James M. Provenzale, Roger E. McLendon, et al. “Phase II trial of temozolomide in patients with progressive low-grade glioma.” J Clin Oncol 21, no. 4 (February 15, 2003): 646–51. https://doi.org/10.1200/JCO.2003.01.009.
    Full Text Link to Item
  - Vokes, Everett E., James E. Herndon, Jeffrey Crawford, Kenneth A. Leopold, Michael C. Perry, Antonius A. Miller, and Mark R. Green. “Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.” J Clin Oncol 20, no. 20 (October 15, 2002): 4191–98. https://doi.org/10.1200/JCO.2002.03.054.
    Full Text Link to Item
  - Elias, Anthony D., Parvesh Kumar, James Herndon, Arthur T. Skarin, David J. Sugarbaker, and Mark R. Green. “Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer.” Clin Lung Cancer 4, no. 2 (September 2002): 95–103. https://doi.org/10.3816/clc.2002.n.019.
    Full Text Link to Item
  - Gururangan, Sridharan, Christina M. Cavazos, David Ashley, James E. Herndon, Carol S. Bruggers, Albert Moghrabi, Deborah L. Scarcella, et al. “Phase II study of carboplatin in children with progressive low-grade gliomas.” J Clin Oncol 20, no. 13 (July 1, 2002): 2951–58. https://doi.org/10.1200/JCO.2002.12.008.
    Full Text Link to Item
  - Marom, Edith M., Jeremy J. Erasmus, James E. Herndon, Chunfeng Zhang, and H Page McAdams. “Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions.” Ajr Am J Roentgenol 179, no. 1 (July 2002): 105–8. https://doi.org/10.2214/ajr.179.1.1790105.
    Full Text Link to Item
  - Kornblith, Alice B., James E. Herndon, Lewis R. Silverman, Erin P. Demakos, Rosalie Odchimar-Reissig, James F. Holland, Bayard L. Powell, et al. “Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.” J Clin Oncol 20, no. 10 (May 15, 2002): 2441–52. https://doi.org/10.1200/JCO.2002.04.044.
    Full Text Link to Item
  - Rasheed, Ahmed, James E. Herndon, Timothy T. Stenzel, Jacqueline G. M. Raetz, Jason Kendelhardt, Henry S. Friedman, Allan H. Friedman, Darell D. Bigner, Sandra H. Bigner, and Roger E. McLendon. “Molecular markers of prognosis in astrocytic tumors.” Cancer 94, no. 10 (May 15, 2002): 2688–97. https://doi.org/10.1002/cncr.10544.
    Full Text Link to Item
  - Marom, Edith M., Sarah Sarvis, James E. Herndon, and Edward F. Patz. “T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET.” Radiology 223, no. 2 (May 2002): 453–59. https://doi.org/10.1148/radiol.2232011131.
    Full Text Link to Item
  - Naughton, M. J., J. E. Herndon, S. A. Shumaker, A. A. Miller, A. B. Kornblith, D. Chao, and J. Holland. “The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033.” Qual Life Res 11, no. 3 (May 2002): 235–48. https://doi.org/10.1023/a:1015257121369.
    Full Text Link to Item
  - Quinn, Jennifer A., James Pluda, M Eileen Dolan, Shannon Delaney, Richard Kaplan, Jeremy N. Rich, Allan H. Friedman, et al. “Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.” J Clin Oncol 20, no. 9 (May 1, 2002): 2277–83. https://doi.org/10.1200/JCO.2002.09.084.
    Full Text Link to Item
  - D’Cunha, Jonathan, Angela L. Corfits, James E. Herndon, Jeffrey A. Kern, Leslie J. Kohman, G Alexander Patterson, Robert A. Kratzke, and Michael A. Maddaus. “Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761.” J Thorac Cardiovasc Surg 123, no. 3 (March 2002): 484–91. https://doi.org/10.1067/mtc.2002.119883.
    Full Text Link to Item
  - Reardon, David A., Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Ilkcan Cokgor, et al. “Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.” J Clin Oncol 20, no. 5 (March 1, 2002): 1389–97. https://doi.org/10.1200/JCO.2002.20.5.1389.
    Full Text Link to Item
  - Blackstock, A William, James E. Herndon, Electra D. Paskett, Michael C. Perry, Stephen L. Graziano, Joseph J. Muscato, Michael P. Kosty, et al. “Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B.” J Natl Cancer Inst 94, no. 4 (February 20, 2002): 284–90. https://doi.org/10.1093/jnci/94.4.284.
    Full Text Link to Item
  - Lyss, Alan P., James E. Herndon, Thomas J. Lynch, Andrew T. Turrisi, Dorothy M. Watson, Sara J. Grethlein, and Mark R. Green. “Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).” Clin Lung Cancer 3, no. 3 (February 2002): 205–10. https://doi.org/10.3816/clc.2002.n.004.
    Full Text Link to Item
  - Johnson, Elizabeth A., David S. Klimstra, James E. Herndon, Edison Catalano, George P. Canellos, Stephen L. Graziano, Jeffrey A. Kern, and Mark R. Green. “Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer.” Cancer Invest 20, no. 5–6 (2002): 686–92. https://doi.org/10.1081/cnv-120003537.
    Full Text Link to Item
  - Rocha Lima, Caio Max S., James E. Herndon, Michael Kosty, Gerald Clamon, and Mark R. Green. “Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B.” Cancer 94, no. 1 (January 1, 2002): 181–87. https://doi.org/10.1002/cncr.10174.
    Full Text Link to Item
  - Heyneman, L. E., J. E. Herndon, P. C. Goodman, and E. F. Patz. “Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening.” Cancer 92, no. 12 (December 15, 2001): 3051–55. https://doi.org/10.1002/1097-0142(20011215)92:12<3051::aid-cncr10106>3.0.co;2-s.
    Full Text Link to Item
  - Heyneman, L. E., J. E. Herndon, P. C. Goodman, and E. F. Patz. “Stage distribution in patients with a small (.” Cancer 92, no. 12 (December 2001): 3051–55.
  - Kosty, M. P., J. E. Herndon, N. J. Vogelzang, H. L. Kindler, and M. R. Green. “High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.” Lung Cancer 34, no. 2 (November 2001): 289–95. https://doi.org/10.1016/s0169-5002(01)00250-1.
    Full Text Link to Item
  - Marom, E. M., S. Sarvis, J. E. Herndon, and E. F. Patz. “Accuracy of positron emission tomography with fluorodeoxyglucose in T1 lung cancer.” Radiology 221 (November 1, 2001): 408–408.
    Link to Item
  - D’Amico, T. A., T. A. Aloia, M. B. Moore, D. H. Conlon, J. E. Herndon, M. S. Kinch, and D. H. Harpole. “Predicting the sites of metastases from lung cancer using molecular biologic markers.” Ann Thorac Surg 72, no. 4 (October 2001): 1144–48. https://doi.org/10.1016/s0003-4975(01)02979-4.
    Full Text Link to Item
  - Gururangan, S., L. Cokgor, J. N. Rich, S. Edwards, M. L. Affronti, J. A. Quinn, J. E. Herndon, et al. “Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.” Neuro Oncol 3, no. 4 (October 2001): 246–50. https://doi.org/10.1093/neuonc/3.4.246.
    Full Text Link to Item
  - Aloia, T. A., D. H. Harpole, C. E. Reed, C. Allegra, M. B. Moore, J. E. Herndon, and T. A. D’Amico. “Tumor marker expression is predictive of survival in patients with esophageal cancer.” Ann Thorac Surg 72, no. 3 (September 2001): 859–66. https://doi.org/10.1016/s0003-4975(01)02838-7.
    Full Text Link to Item
  - Anscher, M. S., L. B. Marks, T. D. Shafman, R. Clough, H. Huang, A. Tisch, M. Munley, et al. “Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation.” J Clin Oncol 19, no. 17 (September 1, 2001): 3758–65. https://doi.org/10.1200/JCO.2001.19.17.3758.
    Full Text Link to Item
  - Graziano, S. L., A. Tatum, J. E. Herndon, J. Box, V. Memoli, M. R. Green, and J. A. Kern. “Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.” Lung Cancer 33, no. 2–3 (August 2001): 115–23. https://doi.org/10.1016/s0169-5002(01)00183-0.
    Full Text Link to Item
  - Marom, E. M., T. A. Aloia, M. B. Moore, M. Hara, J. E. Herndon, D. H. Harpole, P. C. Goodman, and E. F. Patz. “Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer.” Lung Cancer 33, no. 2–3 (August 2001): 99–107. https://doi.org/10.1016/s0169-5002(00)00250-6.
    Full Text Link to Item
  - Salgia, R., D. Harpole, J. E. Herndon, E. Pisick, A. Elias, and A. T. Skarin. “Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer.” Anticancer Research 21, no. 2 B (June 11, 2001): 1241–46.
  - Kornblith, A. B., J. E. Herndon, E. Zuckerman, P. A. Godley, D. Savarese, N. J. Vogelzang, and N. J. Cancer and Leukemia Group B (CALGB). “The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.” Ann Oncol 12, no. 5 (May 2001): 633–41. https://doi.org/10.1023/a:1011102619058.
    Full Text Link to Item
  - Harpole, D. H., M. B. Moore, J. E. Herndon, T. Aloia, T. A. D’Amico, T. Sporn, A. Parr, I. Linoila, and C. Allegra. “The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.” Clin Cancer Res 7, no. 3 (March 2001): 562–69.
    Link to Item
  - Salgia, R., D. Harpole, J. E. Herndon, E. Pisick, A. Elias, and A. T. Skarin. “Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer.” Anticancer Res 21, no. 2B (March 2001): 1241–46.
    Link to Item
  - Kindler, H. L., F. Millard, J. E. Herndon, N. J. Vogelzang, Y. Suzuki, and M. R. Green. “Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.” Lung Cancer 31, no. 2–3 (February 2001): 311–17. https://doi.org/10.1016/s0169-5002(00)00166-5.
    Full Text Link to Item
  - Maguire, P. D., L. B. Marks, G. S. Sibley, J. E. Herndon, R. W. Clough, K. L. Light, M. L. Hernando, P. A. Antoine, and M. S. Anscher. “73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.” J Clin Oncol 19, no. 3 (February 1, 2001): 705–11. https://doi.org/10.1200/JCO.2001.19.3.705.
    Full Text Link to Item
  - Niell, H. B., M. C. Perry, G. Clamon, J. Crawford, A. A. Miller, J. Herndon, and M. R. Green. “Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer.” Clin Lung Cancer 2, no. 3 (February 2001): 204–9. https://doi.org/10.3816/clc.2001.n.004.
    Full Text Link to Item
  - Kornblith, A. B., J. E. Herndon, E. Zuckerman, C. M. Viscoli, R. I. Horwitz, M. R. Cooper, L. Harris, et al. “Social support as a buffer to the psychological impact of stressful life events in women with breast cancer.” Cancer 91, no. 2 (January 15, 2001): 443–54. https://doi.org/10.1002/1097-0142(20010115)91:2<443::aid-cncr1020>3.0.co;2-z.
    Full Text Link to Item
  - Aloia, T., G. Bepler, D. Harpole, P. C. Goodman, H. P. McAdams, J. J. Erasmus, J. E. Herndon, and E. F. Patz. “Integration of peripheral blood biomarkers with computed tomography to differentiate benign from malignant pulmonary opacities.” Cancer Detect Prev 25, no. 4 (2001): 336–43.
    Link to Item
  - Cameron, C. L., D. Cella, J. E. Herndon, A. B. Kornblith, E. Zuckerman, E. Henderson, R. B. Weiss, et al. “Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning.” Health Psychol 20, no. 1 (January 2001): 71–75.
    Link to Item
  - Socinski, M. A., L. B. Marks, J. Garst, G. S. Sibley, W. Blackstock, A. Turrisi, J. Herndon, et al. “Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.” Oncologist 6 Suppl 1 (2001): 20–24. https://doi.org/10.1634/theoncologist.6-suppl_1-20.
    Full Text Link to Item
  - Cokgor, I., G. Akabani, C. T. Kuan, H. S. Friedman, A. H. Friedman, R. E. Coleman, R. E. McLendon, et al. “Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.” J Clin Oncol 18, no. 22 (November 15, 2000): 3862–72. https://doi.org/10.1200/JCO.2000.18.22.3862.
    Full Text Link to Item
  - Friedman, H. S., J. Pluda, J. A. Quinn, R. B. Ewesuedo, L. Long, A. H. Friedman, I. Cokgor, et al. “Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.” J Clin Oncol 18, no. 20 (October 15, 2000): 3522–28. https://doi.org/10.1200/JCO.2000.18.20.3522.
    Full Text Link to Item
  - Farrell, M. A., H. P. McAdams, J. E. Herndon, and E. F. Patz. “Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.” Radiology 215, no. 3 (June 2000): 886–90. https://doi.org/10.1148/radiology.215.3.r00jn29886.
    Full Text Link to Item
  - Patz, E. F., S. Rossi, D. H. Harpole, J. E. Herndon, and P. C. Goodman. “Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer.” Chest 117, no. 6 (June 2000): 1568–71. https://doi.org/10.1378/chest.117.6.1568.
    Full Text Link to Item
  - Perry, M. C., D. C. Ihde, J. E. Herndon, M. L. Grossbard, S. J. Grethein, J. N. Atkins, E. E. Vokes, and M. R. Green. “Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.” Lung Cancer 28, no. 1 (April 2000): 63–68. https://doi.org/10.1016/s0169-5002(99)00129-4.
    Full Text Link to Item
  - Akabani, G., I. Cokgor, R. E. Coleman, D. González Trotter, T. Z. Wong, H. S. Friedman, A. H. Friedman, et al. “Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.” Int J Radiat Oncol Biol Phys 46, no. 4 (March 1, 2000): 947–58. https://doi.org/10.1016/s0360-3016(99)00500-3.
    Full Text Link to Item
  - D’Amico, T. A., T. A. Aloia, M. B. Moore, J. E. Herndon, K. R. Brooks, C. L. Lau, and D. H. Harpole. “Molecular biologic substaging of stage I lung cancer according to gender and histology.” Ann Thorac Surg 69, no. 3 (March 2000): 882–86. https://doi.org/10.1016/s0003-4975(99)01522-2.
    Full Text Link to Item
  - Patz, E. F., J. Connolly, and J. Herndon. “Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer.” Ajr Am J Roentgenol 174, no. 3 (March 2000): 769–74. https://doi.org/10.2214/ajr.174.3.1740769.
    Full Text Link to Item
  - Clamon, G., J. Herndon, R. Cooper, A. Y. Chang, J. Rosenman, and M. R. Green. “Radiosensitization with Carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.” Pneumologie 53, no. 5 (December 1, 1999).
  - Patz, E., H. McAdams, J. Erasmus, P. Goodman, D. Culhane, R. Gilkeson, and J. Herndon. “Sclerotherapy for malignant pleural effusions.” Pneumologie 53, no. 2 (December 1, 1999).
  - Patz, E., H. Me Adams, J. Erasmus, P. Goodman, D. Culhane, R. Gilkeson, and J. Herndon. “Sclerotherapy for malignant pleural effusions.” Pneumologie 53, no. 1 (December 1, 1999).
  - Perry, M. C., J. E. Herndon, W. L. Eaton, and M. K. Green. “Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: An update of cancer and leukemia group B study 8083.” Pneumologie 53, no. 2 (December 1, 1999).
  - Kindler, H. L., C. P. Belani, J. E. Herndon, N. J. Vogelzang, Y. Suzuki, and M. R. Green. “Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.” Cancer 86, no. 10 (November 15, 1999): 1985–91.
    Link to Item
  - Hara, M., H. P. McAdams, J. J. Vredenburgh, J. E. Herndon, and E. F. Patz. “Thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation: incidence and significance in patients with breast cancer.” Ajr Am J Roentgenol 173, no. 5 (November 1999): 1341–44. https://doi.org/10.2214/ajr.173.5.10541115.
    Full Text Link to Item
  - Marom, E. M., H. P. McAdams, J. J. Erasmus, P. C. Goodman, D. K. Culhane, R. E. Coleman, J. E. Herndon, and E. F. Patz. “Staging non-small cell lung cancer with whole-body PET.” Radiology 212, no. 3 (September 1999): 803–9. https://doi.org/10.1148/radiology.212.3.r99se21803.
    Full Text Link to Item
  - Maguire, P. D., G. S. Sibley, S. M. Zhou, T. A. Jamieson, K. L. Light, P. A. Antoine, J. E. Herndon, M. S. Anscher, and L. B. Marks. “Clinical and dosimetric predictors of radiation-induced esophageal toxicity.” Int J Radiat Oncol Biol Phys 45, no. 1 (August 1, 1999): 97–103. https://doi.org/10.1016/s0360-3016(99)00163-7.
    Full Text Link to Item
  - Patz, E. F., J. J. Erasmus, H. P. McAdams, J. E. Connolly, E. M. Marom, P. C. Goodman, R. A. Leder, M. T. Keogan, and J. E. Herndon. “Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax.” Radiology 212, no. 1 (July 1999): 56–60. https://doi.org/10.1148/radiology.212.1.r99jl1956.
    Full Text Link to Item
  - Steele, G. D., J. E. Herndon, R. Bleday, A. Russell, A. Benson, M. Hussain, A. Burgess, J. E. Tepper, and R. J. Mayer. “Sphincter-sparing treatment for distal rectal adenocarcinoma.” Ann Surg Oncol 6, no. 5 (July 1999): 433–41. https://doi.org/10.1007/s10434-999-0433-5.
    Full Text Link to Item
  - Vogelzang, N. J., J. E. Herndon, A. Miller, G. Strauss, G. Clamon, F. M. Stewart, J. Aisner, et al. “High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.” Ann Oncol 10, no. 5 (May 1999): 597–600. https://doi.org/10.1023/a:1026438215309.
    Full Text Link to Item
  - D’Amico, T. A., M. Massey, J. E. Herndon, M. B. Moore, and D. H. Harpole. “A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.” J Thorac Cardiovasc Surg 117, no. 4 (April 1999): 736–43. https://doi.org/10.1016/s0022-5223(99)70294-1.
    Full Text Link to Item
  - Clamon, G., J. Herndon, R. Cooper, A. Y. Chang, J. Rosenman, and M. R. Green. “Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.” J Clin Oncol 17, no. 1 (January 1999): 4–11. https://doi.org/10.1200/JCO.1999.17.1.4.
    Full Text Link to Item
  - Herndon, J. E., S. Fleishman, A. B. Kornblith, M. Kosty, M. R. Green, and J. Holland. “Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?” Cancer 85, no. 2 (January 1999): 333–40. https://doi.org/10.1002/(sici)1097-0142(19990115)85:2<333::aid-cncr10>3.0.co;2-q.
    Full Text
  - Marom, E. M., E. F. Patz, J. J. Erasmus, H. P. McAdams, P. C. Goodman, and J. E. Herndon. “Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis.” Radiology 210, no. 1 (January 1999): 277–81. https://doi.org/10.1148/radiology.210.1.r99dc04277.
    Full Text Link to Item
  - Shieh, D. B., J. Godleski, J. E. Herndon, T. Azuma, H. Mercer, D. J. Sugarbaker, and D. J. Kwiatkowski. “Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression.” Cancer 85, no. 1 (January 1, 1999): 47–57. https://doi.org/10.1002/(sici)1097-0142(19990101)85:1<47::aid-cncr7>3.0.co;2-l.
    Full Text Link to Item
  - Choi, N. C., J. E. Herndon, J. Rosenman, R. W. Carey, C. T. Chung, S. Bernard, L. Leone, S. Seagren, and M. Green. “Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.” J Clin Oncol 16, no. 11 (November 1998): 3528–36. https://doi.org/10.1200/JCO.1998.16.11.3528.
    Full Text Link to Item
  - Friedman, H. S., D. M. Kokkinakis, J. Pluda, A. H. Friedman, I. Cokgor, M. M. Haglund, D. M. Ashley, et al. “Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.” J Clin Oncol 16, no. 11 (November 1998): 3570–75. https://doi.org/10.1200/JCO.1998.16.11.3570.
    Full Text Link to Item
  - Herndon, J. E. “A design alternative for two-stage, phase II, multicenter cancer clinical trials.” Control Clin Trials 19, no. 5 (October 1998): 440–50. https://doi.org/10.1016/s0197-2456(98)00012-9.
    Full Text Link to Item
  - Ahuja, V., R. E. Coleman, J. Herndon, and E. F. Patz. “The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma.” Cancer 83, no. 5 (September 1, 1998): 918–24.
    Link to Item
  - Graziano, S. L., J. A. Kern, J. E. Herndon, A. Tatum, M. L. Brisson, V. Memoli, D. Sugarbaker, A. T. Skarin, H. Kreisman, and M. R. Green. “Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study.” Lung Cancer 21, no. 3 (September 1998): 203–11. https://doi.org/10.1016/s0169-5002(98)00063-4.
    Full Text Link to Item
  - Mehdi, S. A., M. C. Perry, J. E. Herndon, J. Crawford, R. Young, and S. L. Graziano. “A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.” J Interferon Cytokine Res 18, no. 8 (August 1998): 623–27. https://doi.org/10.1089/jir.1998.18.623.
    Full Text Link to Item
  - Kwiatkowski, D. J., D. H. Harpole, J. Godleski, J. E. Herndon, D. B. Shieh, W. Richards, R. Blanco, H. J. Xu, G. M. Strauss, and D. J. Sugarbaker. “Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.” J Clin Oncol 16, no. 7 (July 1998): 2468–77. https://doi.org/10.1200/JCO.1998.16.7.2468.
    Full Text Link to Item
  - Perry, M. C., J. E. Herndon, W. L. Eaton, and M. R. Green. “Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083.” J Clin Oncol 16, no. 7 (July 1998): 2466–67. https://doi.org/10.1200/JCO.1998.16.7.2466.
    Full Text Link to Item
  - Bigner, D. D., M. T. Brown, A. H. Friedman, R. E. Coleman, G. Akabani, H. S. Friedman, W. L. Thorstad, et al. “Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.” J Clin Oncol 16, no. 6 (June 1998): 2202–12. https://doi.org/10.1200/JCO.1998.16.6.2202.
    Full Text Link to Item
  - Ahles, T. A., P. M. Silberfarb, J. Herndon, L. H. Maurer, A. B. Kornblith, J. Aisner, M. C. Perry, et al. “Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B.” J Clin Oncol 16, no. 5 (May 1998): 1954–60. https://doi.org/10.1200/JCO.1998.16.5.1954.
    Full Text Link to Item
  - Assi, Z., J. L. Caruso, J. Herndon, and E. F. Patz. “Cytologically proved malignant pleural effusions: distribution of transudates and exudates.” Chest 113, no. 5 (May 1998): 1302–4. https://doi.org/10.1378/chest.113.5.1302.
    Full Text Link to Item
  - Graham, M. L., B. L. Asselin, J. E. Herndon, J. R. Casey, S. Chaffee, G. H. Ciocci, C. W. Daeschner, et al. “Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia.” Bone Marrow Transplantation 21, no. 9 (May 1998): 879–85. https://doi.org/10.1038/sj.bmt.1701223.
    Full Text
  - Patz, E. F., H. P. McAdams, J. J. Erasmus, P. C. Goodman, D. K. Culhane, R. C. Gilkeson, and J. Herndon. “Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage.” Chest 113, no. 5 (May 1998): 1305–11. https://doi.org/10.1378/chest.113.5.1305.
    Full Text Link to Item
  - Samuels, B. L., J. E. Herndon, D. C. Harmon, R. Carey, J. Aisner, J. M. Corson, Y. Suzuki, M. R. Green, and N. J. Vogelzang. “Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.” Cancer 82, no. 8 (April 15, 1998): 1578–84.
    Link to Item
  - Herndon, J. E., M. R. Green, A. P. Chahinian, J. M. Corson, Y. Suzuki, and N. J. Vogelzang. “Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.” Chest 113, no. 3 (March 1998): 723–31. https://doi.org/10.1378/chest.113.3.723.
    Full Text Link to Item
  - Kornblith, A. B., J. E. Herndon, E. Zuckerman, D. F. Cella, E. Cherin, S. Wolchok, R. B. Weiss, et al. “Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B.” Ann Oncol 9, no. 3 (March 1998): 297–306. https://doi.org/10.1023/a:1008297130258.
    Full Text Link to Item
  - Clamon, G., J. Herndon, W. Akerley, and M. Green. “Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B.” Lung Cancer 19, no. 1 (January 1998): 25–29. https://doi.org/10.1016/s0169-5002(97)00070-6.
    Full Text Link to Item
  - Ryan, C. W., J. Herndon, and N. J. Vogelzang. “A review of chemotherapy trials for malignant mesothelioma.” Chest 113, no. 1 Suppl (January 1998): 66S-73S. https://doi.org/10.1378/chest.113.1_supplement.66s.
    Full Text Link to Item
  - Greenberg, D. B., A. B. Kornblith, J. E. Herndon, E. Zuckerman, C. A. Schiffer, R. B. Weiss, R. J. Mayer, S. M. Wolchok, and J. C. Holland. “Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress.” Cancer 80, no. 10 (November 15, 1997): 1936–44. https://doi.org/10.1002/(sici)1097-0142(19971115)80:10<1936::aid-cncr10>3.0.co;2-z.
    Full Text Link to Item
  - Maurer, L. H., J. E. Herndon, D. R. Hollis, J. Aisner, R. W. Carey, A. T. Skarin, M. C. Perry, et al. “Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.” J Clin Oncol 15, no. 11 (November 1997): 3378–87. https://doi.org/10.1200/JCO.1997.15.11.3378.
    Full Text Link to Item
  - Herndon, J. E., S. Fleishman, M. P. Kosty, and M. R. Green. “A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931.” Control Clin Trials 18, no. 4 (August 1997): 286–300. https://doi.org/10.1016/0197-2456(96)00116-x.
    Full Text Link to Item
  - Vokes, E. E., K. A. Leopold, J. Herndon, and M. R. Green. “Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer.” Seminars in Oncology 24, no. 3 SUPPL. 8 (July 15, 1997).
  - Vokes, E. E., K. A. Leopold, J. Herndon, and M. R. Green. “Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer.” Semin Oncol 24, no. 3 Suppl 8 (June 1997): S8-42-S8-45.
    Link to Item
  - Yogelzang, N. J., J. E. Herndon, C. Cirrincione, D. C. Harmon, K. H. Antman, J. M. Corson, Y. Suzuki, M. L. Citron, and M. R. Green. “Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.” Cancer 79, no. 11 (June 1997): 2237–42. https://doi.org/10.1002/(sici)1097-0142(19970601)79:11<2237::aid-cncr23>3.0.co;2-w.
    Full Text
  - Erasmus, J. J., E. F. Patz, H. P. McAdams, J. G. Murray, J. Herndon, R. E. Coleman, and P. C. Goodman. “Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.” Ajr Am J Roentgenol 168, no. 5 (May 1997): 1357–60. https://doi.org/10.2214/ajr.168.5.9129444.
    Full Text Link to Item
  - Graham, M. L., J. E. Herndon, J. R. Casey, S. Chaffee, G. H. Ciocci, J. P. Krischer, J. Kurtzberg, et al. “High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.” J Clin Oncol 15, no. 5 (May 1997): 1814–23. https://doi.org/10.1200/JCO.1997.15.5.1814.
    Full Text Link to Item
  - Luikart, S. D., J. E. Herndon, D. R. Hollis, M. MacDonald, L. H. Maurer, J. Crawford, G. H. Clamon, et al. “Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).” Am J Clin Oncol 20, no. 1 (February 1997): 24–30. https://doi.org/10.1097/00000421-199702000-00006.
    Full Text Link to Item
  - Dillman, R. O., J. Herndon, S. L. Seagren, W. L. Eaton, and M. R. Green. “Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.” J Natl Cancer Inst 88, no. 17 (September 4, 1996): 1210–15. https://doi.org/10.1093/jnci/88.17.1210.
    Full Text Link to Item
  - Mitchell, E. P., M. C. Perry, S. D. Luikart, C. T. Cirrincione, D. A. Van Echo, J. E. Herndon, L. H. Maurer, G. Clamon, and M. R. Green. “A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study.” Lung Cancer 15, no. 2 (September 1996): 215–23. https://doi.org/10.1016/0169-5002(95)00585-4.
    Full Text Link to Item
  - Brown, M. T., R. E. Coleman, A. H. Friedman, H. S. Friedman, R. E. McLendon, R. Reiman, G. J. Felsberg, et al. “Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.” Clin Cancer Res 2, no. 6 (June 1996): 963–72.
    Link to Item
  - Graziano, S. L., F. H. Valone, J. E. Herndon, J. Crawford, F. Richards, V. B. Rege, G. Clamon, and M. R. Green. “A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.” Lung Cancer 14, no. 2–3 (June 1996): 315–29. https://doi.org/10.1016/0169-5002(96)00556-9.
    Full Text Link to Item
  - Kumar, P., J. Herndon, M. Langer, L. J. Kohman, A. D. Elias, F. C. Kass, W. L. Eaton, S. L. Seagren, M. R. Green, and D. J. Sugarbaker. “Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic Stage IIIA (N2): Analysis of Cancer and Leukemia Group B Protocol 8935.” Cancer 77, no. 11 (June 1, 1996): 2393–99. https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11<2393::AID-CNCR31>3.0.CO;2-Q.
    Full Text
  - Kumar, P., J. Herndon, M. Langer, L. J. Kohman, A. D. Elias, F. C. Kass, W. L. Eaton, S. L. Seagren, M. R. Green, and D. J. Sugarbaker. “Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.” Cancer 77, no. 11 (June 1, 1996): 2393–99. https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11<2393::AID-CNCR31>3.0.CO;2-Q.
    Full Text Link to Item
  - Tross, S., J. Herndon, A. Korzun, A. B. Kornblith, D. F. Cella, J. F. Holland, P. Raich, et al. “Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B.” J Natl Cancer Inst 88, no. 10 (May 15, 1996): 661–67. https://doi.org/10.1093/jnci/88.10.661.
    Full Text Link to Item
  - Harpole, D. H., W. G. Richards, J. E. Herndon, and D. J. Sugarbaker. “Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer.” Ann Thorac Surg 61, no. 5 (May 1996): 1470–76. https://doi.org/10.1016/0003-4975(96)00104-X.
    Full Text Link to Item
  - Halperin, E. C., J. Herndon, S. C. Schold, M. Brown, N. Vick, J. G. Cairncross, D. R. Macdonald, et al. “A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.” Int J Radiat Oncol Biol Phys 34, no. 4 (March 1, 1996): 793–802. https://doi.org/10.1016/0360-3016(95)02025-x.
    Full Text Link to Item
  - Bogart, J. A., D. U’Afson, E. F. McClay, L. Evans, and J. E. Herndon. “Interruptions of modest dose once-daily (QD) thoracic radiotherapy (TRT) do not correlate with outcome in limited small cell lung cancer (L-SCLC): Analysis of CALGB 9235.” Cancer Journal 9, no. 6 (January 1, 1996): 504. https://doi.org/10.1097/00130404-200311000-00074.
    Full Text
  - Bigner, D. D., G. E. Archer, R. E. McLendon, H. S. Friedman, H. E. Fuchs, L. H. Pai, J. E. Herndon, and I. H. Pastan. “Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.” Clin Cancer Res 1, no. 12 (December 1995): 1545–55.
    Link to Item
  - Muscato, J. J., C. Cirrincione, G. Clamon, M. C. Perry, G. Omura, I. Berkowitz, T. Reid, J. E. Herndon, and M. R. Green. “Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study.” Lung Cancer 13, no. 3 (December 1995): 285–94. https://doi.org/10.1016/0169-5002(95)00501-3.
    Full Text Link to Item
  - Patz, E. F., V. J. Lowe, P. C. Goodman, and J. Herndon. “Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma.” Chest 108, no. 6 (December 1995): 1617–21. https://doi.org/10.1378/chest.108.6.1617.
    Full Text Link to Item
  - Herndon, J. E., and F. E. Harrell. “The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables.” Stat Med 14, no. 19 (October 15, 1995): 2119–29. https://doi.org/10.1002/sim.4780141906.
    Full Text Link to Item
  - Harpole, D. H., J. E. Herndon, W. G. Young, W. G. Wolfe, and D. C. Sabiston. “Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence.” Cancer 76, no. 5 (September 1, 1995): 787–96. https://doi.org/10.1002/1097-0142(19950901)76:5<787::aid-cncr2820760512>3.0.co;2-q.
    Full Text Link to Item
  - Miller, A. A., J. E. Herndon, D. R. Hollis, J. Ellerton, A. Langleben, F. Richards, and M. R. Green. “Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.” J Clin Oncol 13, no. 8 (August 1995): 1871–79. https://doi.org/10.1200/JCO.1995.13.8.1871.
    Full Text Link to Item
  - Harpole, D. H., J. R. Marks, W. G. Richards, J. E. Herndon, and D. J. Sugarbaker. “Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.” Clin Cancer Res 1, no. 6 (June 1995): 659–64.
    Link to Item
  - Kosty, M. P., J. E. Herndon, M. R. Green, and O. R. McIntyre. “Placebo-controlled randomized study of hydrazine sulfate in lung cancer.” J Clin Oncol 13, no. 6 (June 1995): 1529–30. https://doi.org/10.1200/JCO.1995.13.6.1529.
    Full Text Link to Item
  - Pastan, I. H., G. E. Archer, R. E. McLendon, H. S. Friedman, H. E. Fuchs, Q. C. Wang, L. H. Pai, J. Herndon, and D. D. Bigner. “Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.” Proc Natl Acad Sci U S A 92, no. 7 (March 28, 1995): 2765–69. https://doi.org/10.1073/pnas.92.7.2765.
    Full Text Link to Item
  - Sugarbaker, D. J., J. Herndon, L. J. Kohman, M. J. Krasna, and M. R. Green. “Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group.” J Thorac Cardiovasc Surg 109, no. 3 (March 1995): 473–83. https://doi.org/10.1016/s0022-5223(95)70278-4.
    Full Text Link to Item
  - Bitran, J. D., M. Green, M. Perry, D. R. Hollis, and J. E. Herndon. “A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB.” Am J Clin Oncol 18, no. 1 (February 1995): 67–70. https://doi.org/10.1097/00000421-199502000-00014.
    Full Text Link to Item
  - Harpole, D. H., J. E. Herndon, W. G. Wolfe, J. D. Iglehart, and J. R. Marks. “A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.” Cancer Res 55, no. 1 (January 1, 1995): 51–56.
    Link to Item
  - Deutsch, M., J. Crawford, K. Leopold, W. Wolfe, W. Foster, J. Herndon, S. Blackwell, and R. Yost. “Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer.” Cancer 74, no. 4 (August 15, 1994): 1243–52. https://doi.org/10.1002/1097-0142(19940815)74:4<1243::aid-cncr2820740411>3.0.co;2-d.
    Full Text Link to Item
  - Seagren, S. L., J. E. Herndon, J. R. Baeker, M. Boles, C. Chung, and M. R. Green. “Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636.” Int J Radiat Oncol Biol Phys 29, no. 5 (July 30, 1994): 1085–88. https://doi.org/10.1016/0360-3016(94)90404-9.
    Full Text Link to Item
  - Vogelzang, N. J., L. B. Weissman, J. E. Herndon, K. H. Antman, M. R. Cooper, J. M. Corson, and M. R. Green. “Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.” J Clin Oncol 12, no. 7 (July 1994): 1436–42. https://doi.org/10.1200/JCO.1994.12.7.1436.
    Full Text Link to Item
  - Green, M. R., M. P. Kosty, J. J. Muscato, S. Graziano, R. O. Dillman, G. H. Clamon, and J. Herndon. “Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience.” Semin Oncol 21, no. 3 Suppl 6 (June 1994): 60–65.
    Link to Item
  - Kosty, M. P., S. B. Fleishman, J. E. Herndon, K. Coughlin, A. B. Kornblith, A. Scalzo, J. C. Morris, J. Mortimer, and M. R. Green. “Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B.” J Clin Oncol 12, no. 6 (June 1994): 1113–20. https://doi.org/10.1200/JCO.1994.12.6.1113.
    Full Text Link to Item
  - Wheeler, R. H., J. E. Herndon, G. H. Clamon, and M. R. Green. “A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B study.” J Immunother Emphasis Tumor Immunol 15, no. 3 (April 1994): 212–16. https://doi.org/10.1097/00002371-199404000-00007.
    Full Text Link to Item
  - Rasheed, B. K., R. E. McLendon, J. E. Herndon, H. S. Friedman, A. H. Friedman, D. D. Bigner, and S. H. Bigner. “Alterations of the TP53 gene in human gliomas.” Cancer Res 54, no. 5 (March 1, 1994): 1324–30.
    Link to Item
  - Clamon, G., J. Herndon, W. Eaton, J. Rosenman, L. H. Maurer, M. R. Cooper, and M. R. Green. “A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B.” Cancer Invest 12, no. 3 (1994): 273–82. https://doi.org/10.3109/07357909409023025.
    Full Text Link to Item
  - Green, M. R., M. P. Kosty, J. J. Muscato, S. Graziano, R. O. Dillman, G. H. Clamon, and J. Herndon. “Nonoperative management of non-small cell lung cancer: The current Cancer and Leukemia Group B experience.” Seminars in Oncology 21, no. 3 SUPPL. 6 (January 1, 1994): 60–65.
  - Kornblith, A. B., D. R. Hollis, E. Zuckerman, A. P. Lyss, G. P. Canellos, M. R. Cooper, J. E. Herndon, C. A. Phillips, J. Abrams, and J. Aisner. “Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.” J Clin Oncol 11, no. 11 (November 1993): 2081–89. https://doi.org/10.1200/JCO.1993.11.11.2081.
    Full Text Link to Item
  - Chahinian, A. P., K. Antman, M. Goutsou, J. M. Corson, Y. Suzuki, C. Modeas, J. E. Herndon, J. Aisner, R. R. Ellison, and L. Leone. “Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.” J Clin Oncol 11, no. 8 (August 1993): 1559–65. https://doi.org/10.1200/JCO.1993.11.8.1559.
    Full Text Link to Item
  - Halperin, E. C., L. Gaspar, J. Imperato, M. Salter, J. Herndon, and S. Dowling. “An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.” Am J Clin Oncol 16, no. 4 (August 1993): 277–83. https://doi.org/10.1097/00000421-199308000-00001.
    Full Text Link to Item
  - Graziano, S. L., J. E. Herndon, F. Richards, S. DiFino, C. Modeas, D. B. Duggan, and M. R. Green. “A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.” Cancer 72, no. 1 (July 1, 1993): 62–68. https://doi.org/10.1002/1097-0142(19930701)72:1<62::aid-cncr2820720114>3.0.co;2-e.
    Full Text Link to Item
  - Clamon, G., J. Herndon, M. C. Perry, H. Ozer, H. Kreisman, T. Maher, J. Ellerton, and M. R. Green. “Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B.” J Natl Cancer Inst 85, no. 4 (February 17, 1993): 316–20. https://doi.org/10.1093/jnci/85.4.316.
    Full Text Link to Item
  - Schold, S. C., J. E. Herndon, P. C. Burger, E. C. Halperin, N. A. Vick, J. G. Cairncross, D. R. Macdonald, E. J. Dropcho, R. Morawetz, and D. D. Bigner. “Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.” J Clin Oncol 11, no. 1 (January 1993): 77–83. https://doi.org/10.1200/JCO.1993.11.1.77.
    Full Text Link to Item
  - Vokes, E. E., A. P. Lyss, J. E. Herndon, B. Cooper, M. C. Perry, V. Vinciguerra, K. Mason-Coughlin, and M. R. Green. “Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B.” Ann Oncol 3, no. 9 (November 1992): 727–32. https://doi.org/10.1093/oxfordjournals.annonc.a058328.
    Full Text Link to Item
  - Lyss, A. P., M. C. Perry, M. Goutsou, K. Propert, J. E. Herndon, K. Mason-Coughlin, and M. R. Green. “Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung cancer. A phase II trial of the Cancer and Leukemia Group B.” Am J Clin Oncol 15, no. 5 (October 1992): 399–404. https://doi.org/10.1097/00000421-199210000-00003.
    Full Text Link to Item
  - Sketch, M. H., P. J. Quigley, J. A. Perez, C. J. Davidson, J. B. Muhlestein, J. E. Herndon, D. D. Glower, H. R. Phillips, R. M. Califf, and R. S. Stack. “Angiographic follow-up after internal mammary artery graft angioplasty.” Am J Cardiol 70, no. 3 (August 1, 1992): 401–3. https://doi.org/10.1016/0002-9149(92)90632-9.
    Full Text Link to Item
  - Strauss, G. M., J. E. Herndon, D. D. Sherman, D. J. Mathisen, R. W. Carey, N. C. Choi, V. B. Rege, C. Modeas, and M. R. Green. “Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.” J Clin Oncol 10, no. 8 (August 1992): 1237–44. https://doi.org/10.1200/JCO.1992.10.8.1237.
    Full Text Link to Item
  - Panella, T. J., D. C. Smith, S. C. Schold, M. P. Rogers, E. P. Winer, R. L. Fine, J. Crawford, J. E. Herndon, and D. L. Trump. “Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.” Cancer Res 52, no. 9 (May 1, 1992): 2456–59.
    Link to Item
  - Glantz, M. J., P. C. Burger, J. E. Herndon, A. H. Friedman, J. G. Cairncross, N. A. Vick, and S. C. Schold. “Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas.” Neurology 41, no. 11 (November 1991): 1741–44. https://doi.org/10.1212/wnl.41.11.1741.
    Full Text Link to Item
  - Nelson, C. L., J. E. Herndon, D. B. Mark, D. B. Pryor, R. M. Califf, and M. A. Hlatky. “Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index.” Am J Cardiol 68, no. 9 (October 1, 1991): 973–75. https://doi.org/10.1016/0002-9149(91)90423-i.
    Full Text Link to Item
  - Davidoff, A. M., J. E. Herndon, N. S. Glover, B. J. Kerns, J. C. Pence, J. D. Iglehart, and J. R. Marks. “Relation between p53 overexpression and established prognostic factors in breast cancer.” Surgery 110, no. 2 (August 1991): 259–64.
    Link to Item
  - Glantz, M. J., J. M. Hoffman, R. E. Coleman, A. H. Friedman, M. W. Hanson, P. C. Burger, J. E. Herndon, W. J. Meisler, and S. C. Schold. “Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.” Ann Neurol 29, no. 4 (April 1991): 347–55. https://doi.org/10.1002/ana.410290403.
    Full Text Link to Item
  - Doll, D., M. Goutsou, S. Graziano, J. Ellerton, J. Bitran, C. Modeas, J. Herndon, M. Perry, and M. Green. “Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study.” Cancer Chemother Pharmacol 29, no. 1 (1991): 71–74. https://doi.org/10.1007/BF00686339.
    Full Text Link to Item
  - Herndon, J. E., and F. E. Harrell. “The restricted cubic spline hazard model.” Communications in Statistics Theory and Methods 19, no. 2 (January 1, 1990): 639–63. https://doi.org/10.1080/03610929008830224.
    Full Text
- Book Sections
  - Herndon, J. E. “Design and statistical analysis of clinical trials for glioma therapy.” In The Duke Glioma Handbook: Pathology, Diagnosis, and Management, 169–89, 2016. https://doi.org/10.1017/CBO9781107588721.009.
    Full Text
- Other Articles
  - Abernethy, A. P., J. E. Herndon, A. Coan, T. Staley, J. L. Wheeler, K. Rowe, S. K. Smith, H. Shaw, and H. K. Lyerly. “Erratum: Phase 2 pilot study of Pathfinders: A psychosocial intervention for cancer patients (Support Care Center DOI 10.1007/s00520-010-0823-z).” Supportive Care in Cancer, March 1, 2011. https://doi.org/10.1007/s00520-010-1076-6.
    Full Text
  - Kwiatkowski, D. J., D. H. Harpole, J. Godlewski, J. E. Herndon, D. B. Shieh, W. Richards, R. Blanco, H. J. Xu, G. M. Strauss, and D. J. Sugarbaker. “Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: Clinical implications.” Pneumologie, December 1, 1999.
- Journal Issues
  - Ghiaseddin, Ashley, David Reardon, Woody Massey, Alex Mannerino, Eric S. Lipp, James E. Herndon, Frances McSherry, et al. “Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.” The Oncologist, February 2018. https://doi.org/10.1634/theoncologist.2017-0501.
    Full Text
- Conference Papers
  - Desjardins, Annick, Matthias Gromeier, James Emmett Herndon, Dina Randazzo, Stevie Threatt, Eric S. Lipp, Elizabeth S. Miller, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.” In Journal of Clinical Oncology, 37:101s-101s. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/JCO.2019.37.15_suppl.2060.
    Full Text Link to Item
  - Peters, Katherine B., Gerald E. Archer, Pamela Norberg, Weihua Xie, Stevie Threatt, Eric S. Lipp, James Emmett Herndon, et al. “Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.” In Journal of Clinical Oncology, 37:e13526–e13526. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e13526.
    Full Text
  - Scott, Jessica, Samantha M. Thomas, James Emmett Herndon, Jeffrey M. Peppercorn, Pamela S. Douglas, Michel Khouri, Chau T. Dang, et al. “Effects of Non-Linear or Linear Aerobic Training (AT) Dosing Regimens on Impaired Cardiovascular (CV) Function in Patients with Operable Breast Cancer: A Randomized Controlled Trial (RCT).” In Journal of Clinical Oncology, 37:541–541. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.541.
    Full Text
  - Ashley, David M., Eric M. Thompson, Daniel Landi, Annick Desjardins, Allan H. Friedman, Stevie Threatt, James E. Herndon, et al. “PHASE 1B STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN.” In Neuro Oncology, 20:93–93. OXFORD UNIV PRESS INC, 2018.
    Link to Item
  - Force, Jeremy, Eda Holl, Michael Brown, Paul Kelly Marcom, Lars Grimm, David Boczkowski, Victoria Frazier, et al. “Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.” In Journal of Clinical Oncology, 36:e12641–e12641. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e12641.
    Full Text
  - Babatunde, Olayode, Collin Kent, Yvonne Mowery, Frances McSherry, James E. Herndon, Ato Wright, Robert Clough, William Sperduto, and John P. Kirkpatrick. “LONG-TERM OUTCOMES FOLLOWING SURGERY AND/OR RADIATION THERAPY IN PATIENTS WITH HIGH-GRADE MENINGIOMA.” In Neuro Oncology, 19:135–135. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Desjardins, Annick, Dina Randazzo, Katherine B. Peters, Margaret O. Johnson, Woody Massey, James E. Herndon, Frances McSherry, et al. “PHASE 2 STUDY OF SYM004 FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM).” In Neuro Oncology, 19:14–14. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Dunn-Pirio, Anastasie, Sarah Woodring, Sujata Panta, Eric S. Lipp, Patrick Healy, James E. Herndon, Eric Fountain, et al. “PERAMPANEL FOR TREATMENT OF REFRACTORY SEIZURES IN PATIENTS WITH GLIOMAS.” In Neuro Oncology, 19:168–168. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Peters, Katherine B., Mary Lou Affronti, Stevie Threatt, Patrick Healy, James E. Herndon, Eric S. Lipp, Sujata Panta, Dina Randazzo, Henry S. Friedman, and Annick Desjardins. “INCREASED FATIGUE ASSOCIATED WITH TUMOR PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS.” In Neuro Oncology, 19:170–170. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Peters, Katherine B., Mary Lou Affronti, Stevie Threatt, Patrick Healy, James E. Herndon, Eric S. Lipp, Sujata Panta, Dina Randazzo, Henry S. Friedman, and Annick Desjardins. “MAINTENANCE OF HEALTH RELATED QUALITY OF LIFE (QOL) BEYOND PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB.” In Neuro Oncology, 19:206–206. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Randazzo, Dina, Frances McSherry, James E. Herndon, Mary Lou Affronti, Patrick Healy, Eric S. Lipp, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “A SINGLE INSTITUTION'S EXPERIENCE EXPLORING THE ASSOCIATION OF INTEGRATIVE MEDICINE AND SURVIVORSHIP IN GLIOBLASTOMA.” In Neuro Oncology, 19:202–202. OXFORD UNIV PRESS INC, 2017.
    Link to Item
  - Desjardins, Annick, John H. Sampson, Gordana Vlahovic, Katherine B. Peters, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).” In Journal of Clinical Oncology, 35:e13533–e13533. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e13533.
    Full Text Link to Item
  - Peters, Katherine B., Stevie Threatt, Patrick Healy, James Emmett Herndon, Eric S. Lipp, Sujata Panta, Dina Randazzo, Gordana Vlahovic, Henry S. Friedman, and Annick Desjardins. “Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.” In Journal of Clinical Oncology, 35:e21636–e21636. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/JCO.2017.35.15_suppl.e21636.
    Full Text Link to Item
  - Randazzo, Dina, Annick Desjardins, Vidyalakshmi Chandramohan, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Stevie Threatt, et al. “Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.” In Journal of Clinical Oncology, 35:e13532–e13532. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e13532.
    Full Text
  - Affronti, Mary Lou, Sarah Woodring, Karen Allen, John Kirkpatrick, Katherine B. Peters, James E. Herndon, Frances McSherry, et al. “Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).” In Support Care Cancer, 24:4365–75, 2016. https://doi.org/10.1007/s00520-016-3276-1.
    Full Text Link to Item
  - Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.” In Journal of Clinical Oncology, 34:2061–2061. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.2061.
    Full Text Link to Item
  - Peters, Katherine B., Sarah Woodring, Patrick Healy, James Emmett Herndon, Eric S. Lipp, Janet Minchew, Ben Zalutsky, et al. “Baseline cognitive function to predict survival in patients with glioblastoma.” In Journal of Clinical Oncology, 34:10125–10125. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.10125.
    Full Text Link to Item
  - Vlahovic, Gordana, Gerald E. Archer, Elizabeth Reap, Annick Desjardins, Katherine B. Peters, Dina Randazzo, Patrick Healy, et al. “Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 34:e13518–e13518. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.e13518.
    Full Text Link to Item
  - Desjardins, Annick, John H. Sampson, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Stevie Threatt, James Emmett Herndon, et al. “Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.” In Journal of Clinical Oncology, 33:2068–2068. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2068.
    Full Text
  - Desjardins, Annick, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Susan Boulton, Woody C. Massey, Eric S. Lipp, et al. “Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.” In Journal of Clinical Oncology, 33:2067–2067. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2067.
    Full Text
  - Friedman, Henry S., Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Susan Boulton, Sarah Woodring, Eric S. Lipp, et al. “Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG).” In Journal of Clinical Oncology, 33:e13004–e13004. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e13004.
    Full Text
  - Ghiaseddin, Ashley, David A. Reardon, Woody Massey, Alexandra Mannerino, Eric S. Lipp, James E. Herndon, Frances McSherry, et al. “Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.” In Journal of Clinical Oncology, 33:2034–2034. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2034.
    Full Text
  - Kim, Jung-Young, Sarah Woodring, Mary Lou Affronti, Dina Randazzo, Frances McSherry, James Emmett Herndon, Eric S. Lipp, et al. “Secondary cancers in long-term survivors of primary glioblastoma.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
    Link to Item
  - Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, Elizabeth Reap, Annick Desjardins, Katherine B. Peters, Dina Randazzo, et al. “Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 33:e13030–e13030. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e13030.
    Full Text
  - Desjardins, Annick, J. H. Sampson, K. B. Peters, T. Ranjan, G. Vlahovic, S. Threatt, J. E. Herndon, et al. “Intratumoral administration of an Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in recurrent glioblastoma(GBM): Preliminary results of the Phase I clinical trial.” In Cancer Research, Vol. 74, 2014. https://doi.org/10.1158/1538-7445.AM2014-CT416.
    Full Text Link to Item
  - Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Jason Watts, Stevie Threatt, et al. “Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).” In Journal of Clinical Oncology, 32:TPS2106–TPS2106. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps2106.
    Full Text
  - Friedman, Henry S., James Emmett Herndon, Frances McSherry, Arliene Ravelo, Eric S. Lipp, Patrick Healy, Katherine B. Peters, et al. “Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice.” In Journal of Clinical Oncology, 32:2082–2082. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.2082.
    Full Text
  - Peters, Katherine B., Sarah Woodring, Mary Lou Affronti, Frances McSherry, James Emmett Herndon, Annick Desjardins, Tulika Ranjan, Gordana Vlahovic, Allan H. Friedman, and Henry S. Friedman. “Long-term survivorship in adult primary glioblastoma: Clinical and neurological outcomes of a large, single-center study.” In Journal of Clinical Oncology, 32:9519–9519. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.9519.
    Full Text
  - Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, Sharon Norman, Annick Desjardins, Katherine B. Peters, Tulika Ranjan, et al. “Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 32:3069–3069. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.3069.
    Full Text
  - Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Emmett Herndon, et al. “Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Desjardins, Annick, John Howard Sampson, Katherine B. Peters, Tulika Ranjan, Gordana Vlahovic, Stevie Threatt, James Emmett Herndon, et al. “Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.” In Journal of Clinical Oncology, Vol. 31, 2013.
    Link to Item
  - Ranjan, Tulika, Katherine B. Peters, Gordana Vlahovic, Lloyd M. Alderson, James Emmett Herndon, Frances McSherry, Stevie Threatt, et al. “Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Gromeier, Matthias, Annick Desjardins, John H. Sampson, Stevie J. E. Threatt, James E. Herndon, Allan Friedman, Henry S. Friedman, and Darell D. Bigner. “ONCOLYTIC POLIOVIRUS IMMUNOTHERAPY OF PRIMARY CNS TUMORS.” In Neuro Oncology, 15:20–20. OXFORD UNIV PRESS INC, 2013.
    Link to Item
  - Affronti, Mary Lou, Sarah Woodring, James E. Herndon, Frances McSherry, Katherine B. Peters, Henry S. Friedman, Annick Desjardins, et al. “A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB.” In Neuro Oncology, 14:156–156. OXFORD UNIV PRESS INC, 2012.
    Open Access Copy Link to Item
  - Desjardins, Annick, Katherine B. Peters, James E. Herndon, Leigh Ann Bailey, Lloyd M. Alderson, Tulika Ranjan, John H. Sampson, et al. “NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH GLIADEL (R) FOLLOWED BY RADIATION THERAPY (RT), TEMOZOLOMIDE AND BEVACIZUMAB, AND POST-RT BEVACIZUMAB AND TEMOZOLOMIDE: A PHASE II STUDY.” In Neuro Oncology, 14:104–104. OXFORD UNIV PRESS INC, 2012.
    Link to Item
  - Peters, Katherine B., David A. Reardon, James J. Vredenburgh, Annick Desjardins, James E. Herndon, April Coan, Frances McSherry, et al. “VORINOSTAT, BEVACIZUMAB, AND METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE GLIOMA: A PHASE I/II CLINICAL TRIAL.” In Neuro Oncology, 14:81–81. OXFORD UNIV PRESS INC, 2012.
    Link to Item
  - Peters, Katherine B., Sarah Woodring, James E. Herndon, Frances McSherry, James J. Vredenburgh, Annick Desjardins, and Henry S. Friedman. “LONG-TERM SURVIVORSHIP IN PRIMARY GLIOBLASTOMA: A FOCUS ON NEUROCOGNITION.” In Neuro Oncology, 14:62–62. OXFORD UNIV PRESS INC, 2012.
    Link to Item
  - Peters, Katherine B., Sarah Woodring, James E. Herndon, Frances McSherry, James J. Vredenburgh, Annick Desjardins, and Henry S. Friedman. “LONG-TERM SURVIVORSHIP IN PRIMARY GLIOBLASTOMA: A FOCUS ON QUALITY OF LIFE.” In Neuro Oncology, 14:158–158. OXFORD UNIV PRESS INC, 2012.
    Link to Item
  - Desjardins, Annick, James J. Vredenburgh, Katherine B. Peters, Stevie Threatt, James Emmett Herndon, John Howard Sampson, Allan H. Friedman, Henry S. Friedman, and David A. Reardon. “Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Friedman, Henry S., Annick Desjardins, Katherine B. Peters, David A. Reardon, John Kirkpatrick, James Emmett Herndon, April D. Coan, et al. “The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Peters, Katherine B., James J. Vredenburgh, Annick Desjardins, Henry S. Friedman, James Emmett Herndon, April D. Coan, Frances McSherry, et al. “Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Vredenburgh, James J., Annick Desjardins, Katherine B. Peters, David A. Reardon, James Emmett Herndon, April D. Coan, John Kirkpatrick, et al. “Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Jiang, X., D. A. Reardon, A. Desjardins, J. J. Vredenburgh, J. A. Quinn, A. D. Austin, J. E. Herndon, R. E. McLendon, and H. S. Friedman. “O6-Methylguanine-DNA Methytransferase (MGMT) Immunohistochemistry as a Predictor of Resistance to Temozolomide in Primary CNS Lymphoma.” In Laboratory Investigation, 91:382A-382A. NATURE PUBLISHING GROUP, 2011.
    Link to Item
  - Desjardins, Annick, David A. Reardon, Katherine B. Peters, James E. Herndon, John P. Kirkpatrick, Henry S. Friedman, and James J. Vredenburgh. “SURVIVAL AND TOXICITY UPDATE OF THE PHASE 2 TRIAL OF BEVACIZUMAB (BV) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS.” In Neuro Oncology, 12:77–77. OXFORD UNIV PRESS INC, 2010.
    Link to Item
  - De Rosa, N., J. E. Herndon, J. Marcello, D. S. Tyler, R. P. Scheri, S. K. Pruitt, J. L. Wheeler, and A. P. Abernethy. “Patterns of Recurrence in Melanoma and the Impact on Survival.” In Annals of Surgical Oncology, 17:S104–5. SPRINGER, 2010.
    Link to Item
  - Friedman, D. R., A. H. Dupont, A. D. Coan, J. E. Herndon, K. L. Rowe, and A. P. Abernethy. “Survivorship care planning needs in diffuse large B-cell lymphoma (DLBCL).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Heimberger, A. B., G. E. Archer, D. A. Mitchell, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, et al. “Epidermal growth factor receptor variant III (EGFRvIII) vaccine ( CDX-110) in GBM.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Lyerly, H. K., T. Staley, J. E. Herndon, A. Coan, J. L. Wheeler, K. Rowe, B. Horne, and A. P. Abernethy. “Impact of a psychosocial intervention on performance status and coping.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Peters, K., A. Desjardins, D. A. Reardon, S. Perry, J. E. Herndon, L. Bailey, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. J. Vredenburgh. “Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Sampson, J. H., G. E. Archer, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, H. S. Friedman, T. Keler, D. A. Reardon, and D. A. Mitchell. “Effect of daclizumab on T-Reg counts and EGFRvIII-specific immune responses in GBM.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Stinchcombe, T. E., L. Hodgson, J. E. Herndon, M. J. Kelley, M. Cicchetti, N. Ramnath, H. B. Niell, J. N. Atkins, M. R. Green, and E. E. Vokes. “Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Vredenburgh, J. J., A. Desjardins, D. A. Reardon, K. Peters, J. E. Herndon, J. Kirkpatrick, S. Gururangan, L. Bailey, A. H. Friedman, and H. S. Friedman. “Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Mitchell, Duane A., Gary E. Archer, Darell D. Bigner, Henry S. Friedman, Denise Lally-Goss, Beth Perry, James E. Herndon, et al. “RNA Transfected Dendritic Cell Vaccines Targeting Human Cytomegalovirus Antigens in Patients with Glioblastoma.” In Molecular Therapy, 17:S93–S93. NATURE PUBLISHING GROUP, 2009.
    Link to Item
  - Scheri, R. P., J. E. Herndon, J. Marcello, J. Wheeler, D. S. Tyler, and A. P. Abernethy. “Mortality burden of melanoma: Metastatic site-specific and temporal trends.” In Journal of Clinical Oncology, 26:9076–9076. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.9076.
    Full Text
  - Uronis, H. E., J. E. Herndon, A. Coan, K. Bronson, J. Wheeler, H. K. Lyerly, M. A. Morse, and A. P. Abernethy. “E/Tablets to collect research-quality, patient-reported data.” In Journal of Clinical Oncology, 26:17528–17528. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.17528.
    Full Text
  - Desjardins, Annick, Daniel Barboriak, James E. Herndon, David Reardon, Jennifer Quinn, Jeremy Rich, Sith Sathornsumetee, Henry Friedman, and James Vredenburgh. “Evaluation of tumor response by dynamic contrast-enhanced magnetic resonance imaging in glioblastoma (gbm) patients treated with bevacizumab (bev) and irinotecan (CPT-11).” In Neuro Oncology, 9:573–74. DUKE UNIV PRESS, 2007.
    Link to Item
  - Affronti, M. L., J. M. Day, J. E. Herndon, J. N. Rich, J. A. Quinn, D. A. Reardon, J. J. Vredenburgh, A. Desjardins, R. E. McLendon, and H. S. Friedman. “Radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy for glioblastoma (GBM) patients.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Desjardins, A., D. P. Barboriak, J. E. Herndon, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, H. S. Friedman, and J. J. Vredenburgh. “Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Goli, K. J., A. Desjardins, J. E. Herndon, J. N. Rich, D. A. Reardon, J. A. Quinn, S. Sathornsumetee, D. A. Bota, H. S. Friedman, and J. J. Vredenburgh. “Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Jones, L., M. L. Affronti, C. W. Bohlin, J. E. Herndon, J. A. Quinn, D. A. Reardon, J. N. Rich, H. S. Friedman, and J. J. Vredenburgh. “Prevalence of osteoporosis in glioma patients on enzyme inducing anticonvulsants (EIAC) and/or glucocorticoids.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Lamont, E. B., J. E. Herndon, J. C. Weeks, I. C. Henderson, R. Lilenbaum, R. L. Schilsky, and N. A. Christakis. “Measuring clinically significant chemotherapy-related toxicities using Medicare claims from CALGB breast and lung cancer trial participants.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Rich, J. N., M. L. Affronti, J. M. Day, J. E. Herndon, J. A. Quinn, D. A. Reardon, J. J. Vredenburgh, A. Desjardins, and H. S. Friedman. “Overall survival of primary glioblastoma (GBM) patients (pts) receiving carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Rowe, K., M. Patwardhan, J. E. Herndon, M. G. Martin, Y. Zafar, M. Morse, and A. P. Abernethy. “Choice of adjuvant and first-line metastatic chemotherapy (CT) for colorectal cancer (CRC) treated in the Carolinas.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Vlahovic, G., T. L. Foster, C. H. Andrews, J. E. Herndon, T. Sporn, M. J. Kelley, M. W. Dewhirst, and Z. Vujaskovic. “Phase I dose escalation, toxicity and dynamic contrast-enhanced (DCE) MRI imaging biomarker study of first line treatment with imatinib (I) and cisplatin (C) plus docetaxel (D) in patients with advanced non-small cell lung cancer (NSCLC).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Zafar, Y., A. P. Abernethy, D. H. Abbott, J. E. Herndon, K. Rowe, J. Kolimaga, L. Conner, M. Patwardhan, S. Grambow, and D. Provenzale. “Comorbidity, age and stage at diagnosis in colorectal cancer (CRC).” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Anscher, M. S., J. Garst, L. B. Marks, N. Larrier, F. Dunphy, J. E. Herndon, R. Clough, C. Marino, Z. Vujaskovic, and S. Zhou. “2498.” In International Journal of Radiation Oncology*Biology*Physics, 66:S487–S487. Elsevier BV, 2006. https://doi.org/10.1016/j.ijrobp.2006.07.910.
    Full Text
  - Affronti, Mary Lou, Jeannette M. Dowell, James E. Herndon, Joan Cahill, Jeremy N. Rich, Jennifer A. Quinn, David A. Reardon, et al. “Overall survival of primary glioblastoma (GBM) patients receiving radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy.” In Neuro Oncology, 8:437–437. DUKE UNIV PRESS, 2006.
    Link to Item
  - Vredenburgh, James, Annick Desjardins, James E. Herndon, David Reardon, Jennifer Quinn, Sith Sathornsumetee, Sridharan Gururangan, Allan Friedman, Darell Bigner, and Henry Friedman. “Bevacizumab and irinotecan is an effective treatment for malignant gliomas.” In Neuro Oncology, 8:454–454. DUKE UNIV PRESS, 2006.
    Link to Item
  - Strauss, G. M., J. E. Herndon, M. A. Maddaus, D. W. Johnstone, E. A. Johnson, D. M. Watson, D. J. Sugarbaker, R. A. Schilsky, E. E. Vokes, and M. R. Green. “Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633.” In Journal of Clinical Oncology, 24:365S-365S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Vredenburgh, J. J., A. Desjardins, J. E. Herndon, J. Quinn, J. Rich, S. Sathornsumetee, H. S. Friedman, D. Reardon, S. Gururangan, and A. Friedman. “Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.” In Journal of Clinical Oncology, 24:59S-59S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Maxwell, Jill A., Stewart P. Johnson, Roger E. McLendon, Francis Ali-Osman, Jennifer A. Quinn, Allan H. Friedman, James E. Herndon, et al. “O-6-alkylguanine-DNA alkyltransferase (AGT) and microsatellite instability (MSI) analyses in malignant glioma.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.
    Link to Item
  - Ali-Osman, F., J. E. Herndon, L. Stephenson, F. Davis, B. McCarthy, D. Reardon, A. Friedman, R. McClendon, H. Friedman, and D. D. Bigner. “Prevalence and prognostic significance of polymorphisms at the glutathione S-transferase M1, M3, P1, and T1 gene loci in human astrocytomas.” In Neuro Oncology, 7:304–304. DUKE UNIV PRESS, 2005.
    Link to Item
  - Lamont, E. B., J. E. Herndon, J. C. Weeks, I. C. Henderson, R. Lilenbaum, R. L. Schilsky, and N. A. Christakis. “Criterion validity of Medicare chemotherapy claims in breast and lung cancer patients.” In Journal of Clinical Oncology, 23:533S-533S. AMER SOC CLINICAL ONCOLOGY, 2005.
    Link to Item
  - Wang, X. F., R. Govindan, J. E. Herndon, R. C. Barrier, D. Watson, R. F. E. E. Vokes, and M. R. Green. “A phase II study of carboplatin, etoposide and exisulind in patients with extensive stage small cell lung cancer: CALGB 30104.” In Journal of Clinical Oncology, 23:660S-660S. AMER SOC CLINICAL ONCOLOGY, 2005.
    Link to Item
  - Cornett, W. R., D. L. Fraker, M. I. Ross, H. A. Briele, A. W. Boddie, R. D. Noyes, J. J. Sussman, L. M. McCall, J. E. Herndon, and D. S. Tyler. “Three month follow up for ACOSOG Z0020, a prospective randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone versus melphalan plus tumor necrosis factor.” In Annals of Surgical Oncology, 12:S18–S18. SPRINGER, 2005.
    Link to Item
  - Wilke, L. G., L. M. McCall, P. W. Whitworth, D. S. Reintgen, A. M. Leitch, S. G. Gabram, A. Lucci, C. E. Cox, J. E. Herndon, and A. E. Giuliano. “Surgical complications associated with sentinel lymph node biopsy: Results from a prospective international cooperative group trial.” In Annals of Surgical Oncology, 12:S27–S27. SPRINGER, 2005.
    Link to Item
  - Strauss, G. M., J. E. Herndon, M. A. Maddaus, D. W. Johnstone, E. A. Johnson, D. H. Harpole, H. H. Gillenwater, et al. “A randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell hung cancer (NSCLC): report of cancer and leukemia group b (CALGB) protocol 9633.” In Lung Cancer, 45:S75–76. ELSEVIER SCI IRELAND LTD, 2004.
    Link to Item
  - Vokes, E. E., J. E. Herndon, M. J. Kelley, D. Watson, M. G. Cicchetti, and M. R. Green. “Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial.” In Journal of Clinical Oncology, 22:618S-618S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Strauss, Gary M., James E. Herndon, Michael A. Maddaus, David W. Johnstone, Elizabeth A. Johnson, David H. Harpole, Heidi H. Gillenwater, et al. “Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633.” In Annals of Oncology, 15:13–14. OXFORD UNIV PRESS, 2004.
    Link to Item
  - McLendon, R. E., R. N. Wiltshire, J. E. Herndon, A. Lloyd, H. S. Friedman, D. D. Bigner, and S. H. Bigner. “Sub-classification of glioblastoma defined by comparative genomic hybridization alterations.” In Journal of Neuropathology and Experimental Neurology, 62:542–542. AMER ASSN NEUROPATHOLOGISTS INC, 2003.
    Link to Item
  - Kelley, M. J., R. J. Folz, E. M. Glaser, J. E. Herndon, J. A. Crowell, M. Perloff, E. Ferdman, L. Gallot, R. Becker, and R. C. Bergan. “Randomized controlled clinical trial of weekly oltipraz in smokers.” In Cancer Epidemiology Biomarkers & Prevention, 11:1169S-1169S. AMER ASSOC CANCER RESEARCH, 2002.
    Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Subject Headings

Selected Grants

Selected Publications

Academic Articles

Book Sections

Other Articles

Journal Issues

Conference Papers